

Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-year Non-randomized Clinical Trial.

Shaminie J. Athinarayanan¹, Rebecca N. Adams¹, Sarah J. Hallberg^{1,2}, Amy L. McKenzie¹, Nasir H. Bhanpuri¹, Wayne W. Campbell³, Jeff S. Volek^{1,4}, Stephen D. Phinney¹, James P. McCarter^{1,5}

¹ Virta Health, 501 Folsom Street, San Francisco, CA 94105, USA

² Indiana University Health Arnett, Lafayette, IN, USA

³ Department of Nutrition Science, Purdue University, West Lafayette, IN, USA

⁴ Department of Human Sciences, The Ohio State University, Columbus, OH, USA

⁵ Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA

Word count: 4054

Tables: 2

Figures: 3

Correspondence:

Shaminie J Athinarayanan, PhD

Clinical Research Scientist

Virta Health Corp.

Mailing address: 501 Folsom Street, San Francisco, CA 94105

E-mail: shaminie@virtahealth.com

Telephone number: (765) 532-9031

DATA SHARING: The complete data and statistical codes are available upon reasonable request.

Conflicts of Interests: SJA, RNA, SJH, ALM, NHB, SDP and JPM are employed by Virta Health Corp and were offered stock options. SDP and JSV are founders of Virta Health Corp. WWC has no conflict of interest to declare.

Financial support: Virta Health Corp. is the study sponsor.

Author contributions: S.J.A, R.N.A, and J.P.M drafted the manuscript. S.J.A, R.N.A, A.L.M, N.H.B, and S.J.H participated in data acquisition and compiling. R.N.A and S.J.A analyzed the data. J.P.M, A.L.M, N.H.B, W.W.C, R.N.A, S.J.A, S.J.H, S.D.P and J.S.V edited the manuscript. All authors approved the final version of the manuscript.

Abbreviations: CCI, continuous care intervention; UC, usual care; T2D, type 2 diabetes; HbA1c, hemoglobin A1c; CVD, cardiovascular disease; VLCD, very low calorie diet; BMI, body mass index; BHB, beta-hydroxybutyrate; BMD, bone mineral density; CAF, central abdominal fat; A/G, android:gynoid ratio; LELM, lower extremities lean mass; HDL, high density lipoprotein; LDL, low density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; NAFLD, nonalcoholic fatty liver disease; NLF, NAFLD liver fat score; NFS, NAFLD fibrosis score; TSH, thyroid stimulating hormone; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; hsCRP, high sensitive C-reactive protein; WBC, white blood cells; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; SGLT-2, sodium-glucose cotransporter-2 inhibitors; DPP-4, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like-peptide 1 receptor agonists; FFM, fat-free mass; VAT, visceral adipose tissue; GLM, generalized linear model; LMM, linear mixed-effect model; ADA, American Diabetes Association; CLIA, Clinical Laboratory Improvement Amendments; IRB, Institutional Review Board; DXA, dual-energy X-ray absorptiometry

ABSTRACT

OBJECTIVE: Studies on long-term sustainability of low-carbohydrate approaches to treat diabetes are limited. We aim to assess the effects of a continuous care intervention (CCI) on retention, glycemic control, weight, body composition, cardiovascular, liver, kidney, thyroid, inflammatory markers, diabetes medication usage and disease outcomes at 2 years in adults with type 2 diabetes (T2D).

RESEARCH DESIGN AND METHODS: An open label, non-randomized, controlled study with 262 and 87 participants with T2D were enrolled in the CCI and usual care (UC) groups, respectively.

RESULTS: Significant changes from baseline to 2 years in the CCI group included: HbA1c (-12% from 7.7±0.1%); fasting glucose (-18% from 163.67±3.90 mg/dL); fasting insulin (-42% from 27.73±1.26 pmol L⁻¹); weight (-10% from 114.56±0.60 kg); systolic blood pressure (-4% from 131.7±0.9 mmHg); diastolic blood pressure (-4% from 81.8±0.5 mmHg); triglycerides (-22% from 197.2±9.1 mg/dL); HDL-C (+19% from 41.8±0.9 mg/dL), and liver alanine transaminase (-21% from 29.16±0.97 U/L). Spine bone mineral density in the CCI group was unchanged. Glycemic control medication use (excluding metformin) among CCI participants declined (from 56.9% to 26.8%, $P=1.3 \times 10^{-11}$) including prescribed insulin (-62%) and sulfonylureas (-100%). The UC group had no significant changes in these parameters (except uric acid and anion gap) or diabetes medication use. There was also significant resolution of diabetes (reversal, 53.5%; remission, 17.6%) in the CCI group but not in UC. All the reported improvements had p-values <0.00012.

CONCLUSIONS: The CCI sustained long-term beneficial effects on multiple clinical markers of diabetes and cardiometabolic health at 2 years while utilizing less medication. The intervention was also effective in the resolution of diabetes and visceral obesity, with no adverse effect on bone health.

TRIAL REGISTRATION

Clinicaltrials.gov NCT02519309

Introduction

Type 2 diabetes (T2D), obesity, and metabolic disease impact over one billion people and present a challenge to public health and economic growth(1,S34). In the United States, over 30 million people have diabetes and it is a leading cause of morbidity and mortality, especially through increased cardiovascular disease (CVD)(2). The remission rate under usual care is 0.5 - 2%(3) while intensive lifestyle intervention resulted in remission rates (both partial and complete) of 11.5% and 9.2% at 1 and 2 years(4). When lifestyle intervention is insufficient, medications are indicated to manage the disease and slow progression.

When T2D care directed at disease reversal is successful, this includes achievement of restored metabolic health, glycemic control with reduced dependence on medication, and in some cases disease remission. Three non-pharmaceutical approaches have demonstrated high rates of at least temporary T2D diabetes reversal or remission: bariatric surgery, very low calorie diets (VLCD), and nutritional ketosis achieved through carbohydrate restriction(5,6,7). In controlled clinical trials, each approach has demonstrated improved glycemic control and CVD risk factors, reduced pharmaceutical dependence, and weight loss. The three approaches show a similar time-course with glycemic control preceding weight loss by weeks or months, suggesting potential overlap of mechanisms(8,S35,S36).

With bariatric surgery, up to 60% of patients demonstrate T2D remission at 1 year(9). Outcomes at two years and beyond indicate ~50% of patients can achieve ongoing diabetes remission(10,S37). The second Diabetes Surgery Summit recommended using bariatric surgery to treat T2D with support from worldwide medical and scientific societies(10), but both complications and cost limit its widespread use(11,S38). VLCDs providing <900 kcal/day allow rapid discontinuation of most medications, improved glycemic control, and weight loss. This approach is necessarily temporary, however, with weight regain and impaired glucose control typically occurring within 3-6 months of reintroduction of substantial proportions of dietary carbohydrate (6,12,S39,S40).

A third approach to diabetes reversal is sustained dietary carbohydrate restriction. Low-carbohydrate diets have consistently elicited improvements in T2D, metabolic disease, and obesity up to

one year(13,S41); however, longer-term studies and studies including patients prescribed insulin are limited. A low carbohydrate Mediterranean diet caused remission in 14.7% of newly diagnosed diabetes patients at 1 year versus 4.1% with a low-fat diet (14), and a small randomized trial utilizing a ketogenic diet demonstrated improved weight and diabetes control at one year (15). Systematic reviews also corroborate the effectiveness of a low-carbohydrate diet for T2D(16,S42) and it has recently become a consensus recommended dietary option(17). Nonetheless, sustained adherence is considered challenging(17), and an LDL-C increase is sometimes observed(18,S43,S44) with carbohydrate restriction. Given that total LDL-P, small LDL-P, and ApoB tend to improve or remain unchanged, the impact of an isolated increase in LDL-C on CVD risk in the context of this dietary pattern is unknown.

We have previously reported 1 year outcomes of an open-label, non-randomized, controlled, longitudinal study with 262 continuous care intervention (CCI) and 87 usual care (UC) participants with T2D(7). The CCI included telemedicine, health coaching, and guidance in nutritional ketosis using an individualized whole foods diet. Eighty-three percent of CCI participants remained enrolled 1 year and 60% of completers achieved an HbA1c <6.5% while prescribed metformin or no diabetes medication. Weight was reduced and most CVD risk factors improved(19). Here we report the results of this study at 2 years. The primary aims were to investigate the effect of the CCI on retention, glycemic control, and weight. Secondary aims included: (1) investigating the effect of the CCI on bone mineral density, visceral fat composition, cardiovascular risk factors, liver, kidney, thyroid and inflammatory markers; diabetes medication use, and disease outcomes (e.g. diabetes remission, metabolic syndrome); and (2) comparing 2-year outcomes between the CCI and UC groups.

Materials and methods

Study design and participants

The comprehensive study design has been published previously (7,25), and the results presented here are the follow-up 2-year results (*Clinical trials.gov identifier: NCT02519309*). This is an open-label, non-randomized, outpatient study and results presented here include data collected between August, 2015 and May, 2018. Participants aged 21 to 65 years with a confirmed diagnosis of T2D and a body

mass index (BMI) > 25 kg/m². Participants in the CCI accessed a remote care team consisting of a health coach and medical provider and reported routine biomarkers (weight, blood glucose and beta-hydroxybutyrate [BHB]) through a web-based application (app). Participants self-selected between two different CCI educational modes: on-site (n=136, CCI-onsite) or web-based (n=126, CCI-virtual). We also recruited another cohort of participants with T2D (n=87) who were categorized as usual care (UC). Exclusion criteria have been published previously (7,25). A brief description of the study participants and interventions (CCI and UC) are listed in the **supplementary data (Methods section)**. All study participants provided written informed consent and the study was approved by the Franciscan Health Lafayette Institutional Review Board.

Outcomes

Primary Outcomes

The primary outcomes were retention, HbA1c, HOMA-IR-insulin and c-peptide derived (scores, equations in supplemental material A), fasting glucose, fasting insulin, c-peptide and weight.

Secondary Outcomes

Long-term body composition changes assessed in CCI participants included bone mineral density (BMD), abdominal fat content (CAF and A/G ratio), and lower extremities lean mass (LELM). Body composition was not assessed in UC participants. Cardiovascular-, liver-, kidney-, thyroid-related and inflammatory markers were analyzed (Table 1 and Supplementary Table 1). Changes in overall diabetes medication use, use by class, and insulin dose were tracked over the two years of the trial.

The prevalence of T2D (diabetes reversal, partial and complete remission), metabolic syndrome, suspected steatosis and absence of fibrosis were evaluated at 2 years in the CCI and UC groups using the criteria provided in Supplementary Table 2 (assignment references listed in the supplementary). Assignment of metabolic syndrome was based on the presence of three of the five defined criteria according to measured laboratory and anthropometric variables; pharmacological treatment for any of the conditions was not considered.

Adverse events encountered in the study were reported to the Principal Investigator and reviewed by the Institutional Review Board (IRB).

Laboratory and body composition measures

Clinical anthropometrics and laboratory blood analytes measurements were obtained at baseline, 1 year, and 2 years from the CCI and UC participants. Details of the methods were previously published(7,19). All blood analytes were measured at a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. The CCI participants were also assessed for total body composition changes at baseline, 1 and 2 years using dual X-ray absorptiometry (DXA) (Lunar GE Prodigy, Madison, WI) and analyzed using GE Encore software(v11.10, Madison, WI). The details of the DXA procedure and analyses are listed in the **supplementary data (Methods section)**.

Statistical analyses

All analyses were conducted using SPSS statistical software (Version 25.0, Armonk, NY). A detailed description of the statistical method is included in the **supplementary data (Methods section)**. Briefly, we conducted intent-to-treat analyses to assess study outcomes. For continuous study outcomes, linear mixed-effects (LMM) models were used to assess within-group changes from baseline to 2 years and between-group differences at 2 years. For dichotomous disease outcomes, generalized estimating equation models were used. Changes in diabetes medication use and insulin dosage from baseline to 2 years were assessed using McNemar's tests with continuity correction when appropriate and paired t-tests. Available data only was used to assess changes in medication use, which was routinely adjusted as part of the intervention protocol. Data from the two CCI educational groups were combined because no group differences were found, as in our prior time points(7,S45). Completers-only analyses were also conducted for all outcomes and results appear in the supplementary material. For all study analyses, nominal significance levels (P) are presented in the tables. A significance level of $P < 0.0012$ ensures overall simultaneous significance of $P < 0.05$ over the 43 variables using Bonferroni correction.

Results

Participant characteristics

Table 1 presents baseline characteristics of the 262 CCI and 87 UC participants. Participants did not differ between groups in demographic characteristics, except the proportion of African Americans was higher in the CCI group. Baseline characteristics were well-matched between the groups, except for mean weight and BMI, which were higher in the CCI group. There were no significant differences between completers and dropouts on baseline characteristics for either group.

Retention and long-term dietary adherence

One hundred ninety four participants (of 262; 74%) remained enrolled in the CCI at 2 years (Figure 1), as did 78% of the UC group participants (68 of 87). CCI participant-reported reasons for dropout included: intervening life events (e.g. family emergencies), difficulty attending or completing laboratory and clinic visits associated with the trial, and insufficient motivation for participation in the intervention. At both 1 and 2 years, laboratory measured blood BHB was $0.3 \pm 0.0 \text{ mmol L}^{-1}$, about 1.5 fold higher than the baseline value ($0.2 \pm 0.0 \text{ mmol L}^{-1}$). The mean laboratory BHB level was stable from 1 to 2 years, and 61.5% (n=161) of participants reported a blood BHB measurement $\geq 0.5 \text{ mmol L}^{-1}$ in the app at least once between 1 and 2 years.

All adjusted within and between group changes in study outcomes for the CCI and UC groups appear in Table 2.

Glycemic outcomes

From baseline to 2 years (Table 2), significant reductions in HbA1c (0.9% unit decrease, -12% relative to baseline, $P=1.8 \times 10^{-17}$; Figure 2A), C-peptide (-27%, $P=2.2 \times 10^{-16}$), fasting glucose (-18%, $P=6.8 \times 10^{-9}$), fasting insulin (-42%, $P=2.2 \times 10^{-18}$, Figure 2B), insulin-derived HOMA-IR excluding exogenous insulin users (-42%, $P=2.7 \times 10^{-13}$), and C-peptide-derived HOMA-IR (-30%, $P=1.1 \times 10^{-15}$) were observed in the CCI group, whereas no changes occurred in the UC group (Supplementary Figures 1A and 1B) (Table 2). There were also significant between-group (CCI vs. UC) differences observed at 2

years in HbA1c, fasting glucose, fasting insulin, insulin-derived HOMA-IR excluding exogenous users, and C-peptide-derived HOMA-IR, with the CCI group having lower glycemic marker means (Table 2).

Metabolic and body composition outcomes

At 2 years, mean weight change from baseline was -10% ($P=8.8 \times 10^{-28}$; Figure 2C) in the CCI group, whereas no change was observed in the UC group (Supplementary Figure 1C). Among CCI patients, 74% had $\geq 5\%$ weight loss compared to only 14% of UC patients (Supplementary Figure 2; completers analysis). Consistent with the weight loss observed, the CCI group had reductions in abdominal fat content, with decreases in CAF (-15%, $P=1.6 \times 10^{-21}$, Figure 2D) and the A/G ratio (-6%, $P=4.7 \times 10^{-8}$) from baseline to 2 years (Table 2). The CCI group's total spine BMD remained unchanged from baseline to 2 years after correction for multiple comparisons (Table 2). The changes in the average LELM in the CCI are included in the Table 2, and further elaborated in the **supplementary data (Discussion section)**.

Cardiovascular risk factor outcomes

Decreases in systolic (-4%, $P=2.4 \times 10^{-6}$, Figure 2E) and diastolic (-4%, $P=3.3 \times 10^{-5}$, Figure 2F) blood pressures and triglycerides (-22%, $P=6.2 \times 10^{-9}$) were observed in the CCI but not UC group at 2 years (Table 2, Supplementary Figures 3A and 3B). The CCI group's HDL-cholesterol (+19%, $P=2.7 \times 10^{-16}$) and LDL-cholesterol (+11%, $P=1.1 \times 10^{-4}$) both increased from baseline to two years, whereas no changes were observed in the UC group (Table 2). No changes in total cholesterol were observed in either the CCI or UC group. At 2 years, the CCI group had higher HDL-cholesterol, higher LDL-cholesterol, and lower triglycerides than UC. No between-group differences were observed at 2 years for systolic or diastolic blood pressure or total cholesterol (Table 2).

Liver-related outcomes

From baseline to 2 years, the CCI group's ALT (-21%, $P=4.0 \times 10^{-10}$; Table 2, Figure 2G), AST (-12%, $P=5.1 \times 10^{-5}$), ALP (-13%, $P=1.8 \times 10^{-14}$), NLF (-78%, $P=2.9 \times 10^{-25}$) and NFS (-60%, $P=2.3 \times 10^{-9}$) were reduced, whereas no changes were observed in UC (e.g. ALT; Supplementary Figure 3C; Table 2). No bonferroni-corrected group differences were observed for bilirubin, ALT, nor AST at 2 years (Table 2).

Kidney, thyroid, and inflammation outcomes

The eGFR increased in the CCI (+3%, $P=1.6 \times 10^{-4}$, Table 2) but not UC group at 2 years. The UC but not CCI group had increased anion gap and decreased uric acid (Table 2). No bonferroni-corrected within-group changes in BUN, serum creatinine, TSH, or Free T4 were observed in either the CCI or UC group from baseline to 2 years. No between-group differences were observed for any thyroid- or kidney-related markers at 2 years (Table 2).

From baseline to 2 years, decreases in the CCI group's hsCRP (-37%, $P=6.9 \times 10^{-13}$, Table 2, Figure 2H) and white blood cell count (-7%, $P=4.3 \times 10^{-5}$) were observed. No changes were observed in the UC group (Supplementary Figure 3D). At 2 years, both markers of inflammation were lower in the CCI group compared to the UC group (Table 2).

Diabetes Medication

All within-group changes in diabetes medication use among study completers appear in eTable 3 (ns are listed in the table). The proportion of CCI completers taking any diabetes medication (excluding metformin) decreased from 55.7% at baseline to 26.8% at 2 years ($P=1.3 \times 10^{-11}$, Figure 3A). Reductions in the use of diabetes medication classes included insulin (29.8% at baseline to 11.3% at 2 years, $P=9.1 \times 10^{-9}$) and sulfonylureas (23.7% at baseline and 0% at 2 years, $P=4.2 \times 10^{-12}$). At 2 years, no changes in the proportions of CCI completers taking SGLT-2 inhibitors (10.3% to 3.1%, $P=0.01$), DPP-4 (9.9% to 6.7%, $P=0.42$), GLP-1 agonists (13.4% to 10.8%, $P=0.42$), thiazolidinediones (1.5% to 2.6%, $P=0.73$), or metformin (71.4% to 63.9%, $P=0.05$) were observed after correction for multiple comparisons. No changes in use of any diabetes medication (excluding metformin) or individual diabetes medication classes were observed in the UC completers from baseline to 2 years. The mean dose for insulin-using participants at baseline decreased among CCI participants by 81% ($P=2.6 \times 10^{-12}$) at 2 years, but not in UC participants (+13%, $P=0.45$) (see Figure 3B). For participants who remained insulin-users at 2 years, the mean dose also decreased in the CCI group by 61% ($P=9.2 \times 10^{-5}$) but not UC group (+19%, $P=0.29$). Among participants prescribed each diabetes medication class, the proportion with each dosage change

(eliminated, reduced, unchanged, increased, or newly added) at 2 years in each group appears in Figure 3C.

Disease Outcomes

All within-group changes and between-group differences in disease outcomes among the CCI and UC group participants appear in supplementary Table 4 (intent-to-treat analyses were conducted; all below n=262). The proportion of participants meeting the defined criteria for diabetes reversal at 2 years increased 41.4% (from 12.1% at baseline to 53.5% at 2 years, $P < 0.0 \times 10^{-36}$) in the CCI group, whereas no Bonferroni-corrected change was observed in the UC group (7.1% absolute decrease, $P = 0.04$). In addition, diabetes remission (partial or complete) was observed in 46 (17.6%) participants in the CCI group and two (2.4%) of the UC participants at 2 years. Complete remission was observed in 17 (6.7%) CCI participants and none (0%) of the UC participants at 2 years.

At 2 years, 27.2% of CCI participants and 6.5% of UC patients showed resolution of metabolic syndrome. The proportion of participants with metabolic syndrome decreased from baseline to 2 years in the CCI (from 89.1% to 61.9%, $P = 4.9 \times 10^{-15}$) but not UC group. The two years improvements of suspected steatosis and fibrosis status are included in the supplementary Tables 4 and 5.

Safety and adverse events

In the CCI group, there were no reported serious adverse events between one and two years attributed to the intervention or that resulted in discontinuation, including no reported episodes of ketoacidosis or severe hypoglycemia requiring assistance. Adverse events occurring in the first year of intervention (n=6) were previously reported[10]. Details of the adverse events are included in the **supplementary data (Results section)**.

Discussion

Following 2 years of a remote continuous care intervention supporting medical and lifestyle changes, the CCI participants demonstrated improved HbA1c, fasting glucose and insulin, and HOMA-IR. Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists(20,21,S46-S48). The HbA1c reduction of 0.9% with this CCI is comparable to that observed in pharmaceutical trials, but is achieved while discontinuing 67.0% of diabetes-specific prescriptions including most insulin and all sulfonylureas that engender risks for weight gain and hypoglycemia(22,23). Comparable improvements in glycemic control and reduced medication were not observed in UC participants recruited from the same healthcare system, suggesting that the CCI improves diabetes management relative to usual care. Other interventions using carbohydrate restriction reported variable long-term glycemic improvement outcomes(24-26,S49-S51). The 0.9% absolute (12% relative) HbA1c reduction observed at 2 years is consistent with low carbohydrate studies reporting HbA1c reductions of 8-15% at 2 to 3.5 years (25,26,S49,S51) with medication reduction. Two others studies reported no changes in HbA1c from baseline to 2 years, even though the low carbohydrate arm reduced HbA1c in the first 6 months(24,S50). This study observed a modest increase in HbA1c and weight between 1 and 2 years in CCI participants suggesting some reduction in long-term effectiveness. Interestingly, insulin-levels show no regression toward baseline from 1 to 2 years indicating long-term improvement in hyperinsulinemia, an important component of diabetes pathology(8,27).

Criticisms of low-carbohydrate diets relate to poor adherence and long-term sustainability(16,28). In this CCI, self-monitoring combined with continuous remote-monitoring and feedback from the care team, including behavioral support and nutrition advice via the app, may have improved accountability and engagement(S52). In addition to glucose and weight tracking, dietary adherence was monitored by blood ketones. The 2 year BHB increase above baseline demonstrates sustained dietary modification. While laboratory BHB levels were increased from baseline, nutritional ketosis (≥ 0.5 mM) was observed in only a minority (14.1%) of participants at 2 years. On average, patient-measured BHB was ≥ 0.5 mM

for 32.8% of measurements over the 2 years (eFigure 4). This reveals an opportunity to increase adherence to nutritional ketosis for patients not achieving their desired health outcomes while prompting future research investigating the association between dietary adherence and health improvements.

A majority of the CCI participants (53.5%) met criteria for diabetes reversal at 2 years while 17.6% achieved diabetes remission (i.e. glycemic control without medication use) based on intent-to-treat with multiple imputation. The percentage of all CCI enrollees (N=262) with verified reversal and remission requiring both completion of two years of the trial and an obtained laboratory value for HbA1c were 37.8% and 14.9%, respectively. CCI diabetes reversal exceeds remission as metformin prescriptions were usually continued given its role in preventing disease progression(7,29), preserving β -cell function(29) and in treatment of pre-diabetes per guidelines (28). Partial and complete remission rates of 2.4% and 0.2% per year, respectively, have been reported in 122,781 T2D patients receiving standard diabetes care(3). The two-year remission rate (both partial and complete) in the CCI (17.6%) is higher than that achieved through intensive lifestyle intervention (ILI) in the Look AHEAD trial (9.2%)(4). Greater diabetes remission in the CCI versus Look AHEAD ILI could result from differences in the dietary intervention(14), patients' ability to self-select their lifestyle or effectiveness of continuous remote care. Length of time with a T2D diagnosis is a factor in remission, with longer time since diagnosis resulting in lower remission(3,4,6,S53). Despite a mean of 8.4 years since diagnosis among CCI participants, the remission rate was higher than the Look AHEAD trial where its participants had a median of 5 years(4) since diabetes diagnosis.

Participants in the CCI achieved 10% mean weight loss (-11.9kg) at 2 years. CCI weight loss was comparable to observed weight loss following surgical gastric banding (-10.7kg) at 2 years(29). Previous studies consistently report that weight loss increases the likelihood of T2D remission(3,4,6). CCI participants also improved blood pressure, triglycerides, and HDL-cholesterol. Total cholesterol was unchanged and calculated LDL-cholesterol was increased at 2 years, but was not different from the LDL-cholesterol level observed at one year (+0.51, P=0.85). Despite the rise in LDL-cholesterol, the CCI cohort improved in 22 out of 26 CVD markers at one year(19). This includes a decrease in small LDL-

particles and large VLDL-P and an increase in LDL-particle size with no changes in ApoB(19), a marker considered a better predictor of CVD risk than LDL-cholesterol(19,30,S54). Non-elevated LDL cholesterol values together with higher triglycerides and lower HDL-cholesterol are common in patients with abdominal obesity, T2D, and metabolic syndrome(31,S55,S56); these individuals often still have elevated atherogenic lipoproteins such as non-HDL(32,S57), small LDL particles(31,S58), and VLDL(31,S58). In the CCI group, non-HDL cholesterol did not change significantly from baseline to 2 years and several cardiovascular risk factors across various physiological systems improved, suggesting that the rise in LDL-cholesterol may not be associated with increased atherogenic risk(33).

The CCI group had a reduction in visceral fat content, CAF and A/G ratio. This is consistent with other low-carbohydrate interventions reporting visceral fat reduction as a component of weight loss(18,24,34,35,S59). Anatomical distribution of fat around the abdominal area (“android” obesity) is associated with T2D(36,S60) and other comorbidities such as metabolic syndrome(37) and NAFLD(38,S61). The alleviation of visceral fat in the CCI group was concurrent with resolution of metabolic syndrome at 2 years, while sustaining one-year improvements of liver enzymes(7), steatosis and fibrosis (39 in press,S62-S67). While studies in animal models(40,S68,S69) and children treated with ketogenic diets(41,S70) have suggested retardation in skeletal development and reduction in BMD, in this study of T2D adults the CCI group had no change in total spine BMD over two years. Our results are consistent with other adult ketogenic dietary studies that reported no bone mass loss in short-term(34,S71) or long-term follow-up of 2(35,S72) and 5(S73) years. The differing findings of ketogenic diet on bone mass between adults and children could be due to differential effects on developed and mineralized versus developing bones(42).

Strengths and limitations

This study’s strengths include its size and prospective, longitudinal data collection from two participant groups (CCI and UC) which allowed statistical analysis by LMMs to investigate intervention time and treatment effects. While not randomized, the participants’ self-selection of intervention may

contribute to the observed high retention and predicts real-life clinical management of chronic disease. The study also included patients prescribed insulin and with long-standing disease, groups often excluded from prior studies. The multi-component aspect of the intervention involving regular biomarker monitoring and access to a remote care team may have improved the patients' long-term dietary adherence and engagement. The dietary advice including encouraging participants to restrict carbohydrates, moderate protein intake, and eat to satiety may also help in maintaining long-term effectiveness. Weaknesses of this study include the lack of randomization and limited racial diversity. Interpretation of DXA body composition was limited to subregion analyses due to the scanner not accommodating the patients' complete body.

Conclusions

At 2 years, the CCI, including remote medical management with instruction in nutritional ketosis, led to improvements in blood glucose, insulin, HbA1c, weight, blood pressure, triglycerides, liver function, and inflammation and reduced dependence upon medication. These long-term benefits were achieved concurrent with reduced prevalence of metabolic syndrome and visceral adiposity. The CCI had no adverse effect on bone mineral density. The CCI group also had higher prevalence of diabetes reversal and remission compared to the UC group following a standard diabetes care program. These results provide strong evidence that sustained improvement in diabetes status can be achieved through the continuous remote monitoring and accountability mechanisms provided by this multi-component CCI including recommendations for low carbohydrate nutrition.

References

1. World Health Organization. (2016). Global report on diabetes. World Health Organization. <http://www.who.int/iris/handle/10665/204871>.
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US. Dept of Health and Human Services; 2017.
3. Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: The diabetes & aging study. *Diabetes Care* 2014; 37: 3188-3195.
4. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. *JAMA* 2012; 308: 2489-2496.
5. Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *JAMA* 2014; 311: 2297-2304.
6. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *The Lancet* 2018; 391: 541-551.
7. Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. *Diabetes Ther* 2018; 9: 583-612.
8. Taylor R. Type 2 Diabetes: Etiology and reversibility. *Diabetes Care* 2013; 36: 1047-1055.
9. Dicker D, Yahalom R, Comaneshter DS, Vinker S. Long-term outcomes of three types of bariatric surgery on obesity and type 2 diabetes control and remission. *Obesity Surg* 2016; 26: 1814-1820.
10. Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by International Diabetes Organizations. *Diabetes Care* 2016; 39: 861-867.

11. Berger ER, Huffman KM, Fraker T, et al. Prevalence and risk factors for bariatric surgery readmissions: Findings from 130,007 admissions in the metabolic and bariatric surgery accreditation and quality improvement program. *Ann Surg* 2018; 267: 122-131.
12. Snel M, Jonker JT, Hammer S, et al. Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients. *Obesity* 2012; 20: 1572-1576.
13. Yamada Y, Uchida J, Izumi H, et al. A non-calorie-restricted low-carbohydrate diet is effective as an alternative therapy for patients with type 2 diabetes. *Intern Med* 2014; 53: 13-19.
14. Esposito K, Maiorino MI, Petrizzo M, Bellastella G, Giugliano D. The effects of a Mediterranean diet on the need for diabetes drugs and remission of newly diagnosed type 2 diabetes: follow-up of a randomized trial. *Diabetes Care* 2014; 37: 1824-1830
15. Saslow LR, Daubenmier JJ, Moskowitz JT, et al. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. *Nutrition and Diabetes* 2017; 304: doi 10.1038/s41387-017-0006-9.
16. Wheeler ML, Dunbar SA, Jaacks LM, et al. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. *Diabetes Care* 2012; 35: 434-455.
17. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018; <https://doi.org/10.2337/dci18-0033>.
18. Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. *Lipids* 2009; 44: 297-309.
19. Bhanpuri NH, Hallberg SJ, Williams PT, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate

- restriction at 1 year: an open label, non-randomized, controlled study. *Cardiovasc Diabetol* 2018; 17: 56 <https://doi.org/10.1186/s12933-018-0698-8>.
20. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013; 369: 1317-1326.
21. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2016; 375: 1834-1844.
22. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; 358: 2545-2559.
23. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. *Diabetes Care* 1993; 16:21-31.
24. Guldbrand H, Dizdar B, Bunjaku B, et al. In type 2 diabetes, randomisation to advice to follow a low-carbohydrate diet transiently improves glycaemic control compared with advice to follow a low-fat diet producing a similar weight loss. *Diabetologia* 2012; 55: 2118-2127.
25. Nielsen JV, Joensson EA. Low carbohydrate diet in type 2 diabetes: stable improvement of bodyweight and glycemic control during 44 months follow-up. *Nutr Metab* 2008; 5: 14 doi:10.1186/1743-7075-5-14
26. Tay J, Thompson CH, Luscombe-Marsh ND, et al. Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial. *Diabetes Obes Metab* 2018; 20: 858-871.
27. Pories WJ and Dohm GL. Diabetes: Have we got it all wrong? Hyperinsulinism as the culprit: surgery provides the evidence. *Diabetes Care* 2012; 35: 2438-2442.
28. Standards of Medical Care in Diabetes-2018: Summary of Revisions. *Diabetes Care* 2018; 41: S1-S1.

29. Xiang AH, Trigo E, Martinez M, et al. Impact of gastric banding versus metformin on β -cell function in adults with impaired glucose tolerance or mild type 2 diabetes. *Diabetes Care* 2018; <https://doi.org/10.2337/dc18-1662>.
30. Sniderman AD, Toth PP, Thanassoulis G, Furberg CD. An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. *J Clin Lipidol* 2016;10:248-258.
31. Welthy FK. How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? *Curr Cardiol Rep* 2013; 15: 400.doi:10.1007/s11886-013-0400-4.
32. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes. *Diabetes Care* 2003; 26: 16-23.
33. Creighton BC, Hyde PN, Maresh CM, Kraemer WJ, Phinney SD, Volek JS. Paradox of hypercholesterolaemia in highly trained, keto-adapted athletes. *BMJ Open Sport Exerc Med* 2008;4: e000429.doi:10.1136/bmjsem-2018-00429.
34. Gomez-Arbelaes D, Bellido D, Castro AI, et al. Body composition changes after very low-calorie-ketogenic diet in obesity evaluated by three standardized methods. *J Clin Endocrinol Metab* 2016; doi: 10.1210/jc.2016-2385
35. Moreno B, Crujeiras AB, Bellido D, Sajoux I, Casanueva FF. Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease. *Endocrine* 2016; 54: 681-690.
36. Levelt E, Pavlides M, Banerjee R, et al. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. *J Am Coll Cardiol* 2016; 68: 53-63.
37. Shah RV, Murthy VL, Abbasi SA, et al. Visceral adiposity and the risk of metabolic syndrome across of body mass index. *JACC Cardiovasc Imaging* 2014; 7: 1221-1235.
38. Mirza MS. Obesity, visceral fat, and NAFLD: Querying the role of adipokines in the progression of nonalcoholic fatty liver disease.

39. Vilar-Gomez E, Athinarayanan SJ, Adams RN, et al. Post-hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally-supported continuous care intervention: an open label, non-randomized, controlled study (in press).
40. Bielohuby M, Matsuura M, Herbach N, et al. Short-term exposure to low-carbohydrate, high-fat diets induces low bone mineral density and reduces bone formation in rats. *J Bone Miner Res*. 2010;25:275–284.
41. Simm PJ, Bicknell-Royle J, Lawrie J, et al. The effect of the ketogenic diet on the developing skeleton. *Epilepsy Res* 2017; 136: 62-66
42. Stagi S, Cavalli L, Iurato C, Seminara S, Brandi ML, de Martino M. Bone metabolism in children and adolescents: main characteristics of the determinants of peak bone mass. *Clin Cases Miner Bone Metab* 2013; 10:172-179.

Table 1. Baseline characteristics

	All		Completers with data		Dropout or missing data		Completers-Dropouts
	N	Mean (SD) or \pm SE	N	Mean (SD) or \pm SE	N	Mean (SD) or \pm SE	Mean \pm SE
Age (years)							
CCI-all education	26	53.8(8.4)	19	54.4(8.2)	68	51.9(8.7)	2.5 \pm 1.2
Usual Care	2	52.3(9.5)	4	51.4(9.4)	19	55.6(9.5)	-4.2 \pm 2.4
CCI-all vs. usual care	87	1.4 \pm 1.1	68	3.0 \pm 1.2		-3.6 \pm 2.4	
African American (%)							
CCI-all education	26	6.9 \pm 1.6	19	6.2 \pm 1.7	68	8.8 \pm 3.5	-2.6 \pm 3.6
Usual Care	2	0.0 \pm 0.0	4	0.0 \pm 0.0	19	0.0 \pm 0.0	—
CCI-all vs. usual care	87	6.9 \pm 1.6*	68	6.2 \pm 1.7*		8.8 \pm 3.5	
Body mass index (kg m ⁻²)							
CCI-all education	25	40.42(8.81)	19	40.41(8.42)	67	40.46(9.90)	-0.05 \pm 1.25
Usual Care	7	36.72(7.26)	0	36.90(7.41)	19	36.11(6.89)	0.79 \pm 1.91
CCI-all vs. usual care	83	3.70 \pm 1.07*	64	3.51 \pm 1.18		4.34 \pm 2.43	
Female (%)							
CCI-all education	26	66.79 \pm 2.92	19	65.98 \pm 3.41	68	69.12 \pm 5.64	-3.14 \pm 6.66
Usual Care	2	58.62 \pm 5.31	4	60.29 \pm 5.98	19	52.63 \pm 11.77	7.66 \pm 12.90
CCI-all vs. usual care	87	8.17 \pm 6.06	68	5.69 \pm 6.76		16.49 \pm 12.35	

Waist circumference (in)							
CCI-all education	21	49.02(5.64)	15	49.04(6.40)	59	48.97(6.89)	0.06±1.00
Usual Care	8	46.41(5.64)	9	46.33(5.63)	19	46.67(5.82)	0.34±1.48
CCI-all vs. usual care	83	2.61±0.81	64	2.71±0.92		2.30±1.75	
Years since type 2 diabetes diagnosis							
CCI-all education	26	8.44(7.22)	19	8.15(7.02)	68	9.25(7.75)	-1.1±1.02
Usual Care	1	7.85(7.32)	3	7.90(7.41)	8	7.38(7.05)	0.53±2.77
CCI-all vs. usual care	71	0.59±0.97	63	0.25±1.03		1.88±2.87	
Glycemic							
Hemoglobin A1c (%)							
CCI-all education	26	7.6(1.5)	19	7.5(1.41)	68	7.9(1.7)	-0.4±0.2
Usual Care	2	7.6(1.8)	4	7.7(1.9)	19	7.41(1.4)	0.3±0.5
CCI-all vs. usual care	87	-0.0±0.2	68	-0.2(0.3)		0.45±0.43	
C-Peptide (nmol L ⁻¹)							
CCI-all education	24	4.36(2.15)	18	4.40(2.15)	63	4.25(2.17)	0.15±0.31
Usual Care	8	4.18(2.48)	5	3.86(2.22)	17	5.35(3.08)	-1.50±0.80
CCI-all vs. usual care	79	0.18±0.29	62	0.54±0.32		-1.10±0.80	
Fasting glucose (mg/dL)							
CCI-all education	25	160.77(61.37)	19	158.01(60.77)	67	168.64(62.86)	-10.63±8.81
Usual Care	8	156.20(72.60)	1	162.07(78.71)	19	135.47(39.85)	26.60±13.27
CCI-all vs. usual care	86	4.57±8.01	67	-4.06±10.57		33.17±15.25	
Fasting Insulin (pmol L ⁻¹)							
CCI-all education		28.56(23.88)		27.37(22.33)	63	32.06(27.86)	-4.70±3.87

Usual Care	24	29.11(24.85)	18	25.54(21.87)	17	42.12(30.95)	-16.58±6.58
CCI-all vs. usual care	8	-0.55±3.12	5	1.83±3.26		-10.05±7.79	
	79		62				
HOMA-IR (insulin derived), all							
CCI-all education	22	8.96(6.17)	16	8.92(6.19)	52	9.10(6.14)	-0.19±0.98
Usual Care	0	10.64(9.12)	8	9.56(8.35)	17	14.52(10.88)	-4.96±2.85
CCI-all vs. usual care	78	-1.68±1.11	61	-0.65±1.17		-5.41±2.77	
HOMA-IR (insulin derived), excluding exogenous users							
CCI-all education	15	8.80(5.64)	12	8.62(5.74)	36	9.41(5.31)	-0.78±1.07
Usual Care	7	9.41(8.35)	1	7.95(6.53)	10	14.09(11.77)	-6.15±2.90
CCI-all vs. usual care	42	-0.61±1.36	32	0.68±1.17		-4.68±3.82	
HOMA-IR (C-peptide derived), all							
CCI-all education	24	11.73(7.40)	18	11.52(6.55)	62	12.33(9.51)	-0.80±1.09
Usual Care	4	11.10(7.56)	2	10.63(7.64)	17	12.80(7.23)	-2.17±2.07
CCI-all vs. usual care	78	0.62±0.97	61	0.89±1.01		-0.47±2.49	

Metabolic and Body Composition

Diabetes reversal (%) ^a							
CCI-all education	26	12.2±2.0	19	12.9±2.4	68	10.3±3.7	2.6±4.6
Usual Care	2	20.7±4.4	4	19.1±4.8	19	26.3±10.4	-7.2±10.6
CCI-all vs. usual care	87	-8.5±4.8	68	-6.2±5.4		-16.0±11.0	

Metabolic syndrome (%)							
CCI-all education	26	88.6±2.0	19	88.7±2.3	68	88.2±4.0	0.4±4.5
Usual Care	2	91.4±3.1	4	93.6±3.2	19	84.2±9.0	9.3±9.2
CCI-all vs. usual care	81	-2.8±4.0	62	-4.9±3.9		4.0±8.7	
Weight-clinic (kgs)							
CCI-all education	25	116.50(25.94)	19	115.97(24.94)	67	117.98(28.72)	-2.00±3.69
Usual Care	7	105.63(22.14)	0	105.32(21.81)	19	106.67(23.82)	-1.35±5.82
CCI-all vs. usual care	83	10.87±3.17*	64	10.65±3.50		11.32±7.21	
Spine bone mineral density (kg)							
CCI-all education	23 8	1.20(0.16)	17 8	1.20(0.15)	60	1.21(0.18)	-0.01±0.03
Central abdominal fat (kg)							
CCI-all education	23 7	5.77(1.69)	17 7	5.72(1.69)	60	5.94(1.72)	-0.22±0.25
Android: gynoid ratio							
CCI-all education	23 8	1.27(0.33)	17 8	1.26(0.33)	60	1.31(0.34)	-0.06±0.05
Lower extremities lean mass (kg)							
CCI-all education	23 8	18.45(4.05)	17 8	18.42(3.94)	60	18.53(4.40)	-0.11±0.61
Cardiovascular							

Systolic blood pressure (mmHg)							
CCI-all education	26	131.9(14.1)	19	132.2(14.2)	68	131.1(13.8)	1.2(2.0)
Usual Care	0	129.8(13.6)	2	129.0(13.6)	18	132.7(13.5)	-3.7(3.7)
CCI-all vs. usual care	79	2.1±1.8	61	3.3±2.1		-1.6±3.6	
Diastolic blood pressure (mmHg)							
CCI-all education	26	82.1(8.3)	19	81.7(8.0)	68	83.4(8.9)	-1.7±1.2
Usual Care	0	82.0(8.9)	2	82.1(8.8)	18	81.8(9.6)	0.3±2.4
CCI-all vs. usual care	79	0.1±1.1	61	-0.4±1.2		1.6±2.4	
Total cholesterol (mg/dL)							
CCI-all education	24	183.6(41.2)	18	181.9(40.3)	63	188.7(43.6)	-6.8±6.0
Usual Care	7	183.8(45.8)	4	186.5(49.3)	17	174.0(28.7)	12.5±12.5
CCI-all vs. usual care	79	-0.2±5.5	62	-4.6±6.3		14.7±11.2	
LDL-cholesterol (mg/dL)							
CCI-all education	23	102.5(32.9)	17	101.1(33.0)	59	106.6(32.6)	-5.5±5.0
Usual Care	2	101.5(36.2)	3	103.8(38.3)	14	92.3(24.8)	11.5±10.8
CCI-all vs. usual care	70	1.0±4.6	56	-2.7±5.3		14.3±9.3	
HDL-cholesterol (mg/dL)							
CCI-all education	24	42.2(13.4)	18	42.5(13.7)	63	41.3(12.7)	1.1±2.0
Usual Care	7	37.6(11.2)	4	38.3(11.5)	17	35.2(10.1)	3.0±3.1
CCI-all vs. usual care	79	4.6±1.7	62	4.2±1.9		6.1±3.3	
Triglycerides (mg/dL)							
CCI-all education	24	197.2(143.4)	18	200.7(153.5)	63	187.1(109.0)	13.5±21.0
Usual Care	7	282.9(401.2)	4	283.7(443.6)	17	280.0(185.0)	3.7±110.5
CCI-all vs. usual care	79	-85.7±46.1	62	-83.0±57.5		-92.9±46.9	

Liver

ALT (Units/L)

CCI-all education	25	30.65(22.77)	19	31.65(24.54)	67	27.79(16.63)	3.86±3.23
Usual Care	7	27.74(19.81)	0	28.31(21.30)	19	25.74(13.59)	2.58±5.17
CCI-all vs. usual care	86	2.90±2.75	67	3.34±3.38		2.05±4.17	

AST (Units/L)

CCI-all education	25	23.69(15.19)	19	24.37(16.79)	67	21.76(9.08)	2.61±2.16
Usual Care	7	23.90(19.39)	0	24.25(21.36)	19	22.63(10.02)	1.62±5.07
CCI-all vs. usual care	86	-0.20±2.04	67	0.12±2.57		-0.87±2.42	

ALP (Units/L)

CCI-all education	25	74.11(22.14)	18	74.32(22.32)	67	73.54(21.79)	0.78±3.15
Usual Care	6	77.36(26.29)	9	78.25(27.67)	19	74.21(21.08)	4.04±6.86
CCI-all vs. usual care	86	-3.25±2.90	67	-3.94±3.39		-0.67±5.62	

Bilirubin (mg/dL)

CCI-all education	25	0.54(0.21)	18	0.55(0.21)	67	0.49(0.18)	0.06±0.03
Usual Care	6	0.55(0.28)	9	0.54(0.27)	19	0.59(0.29)	-0.05±0.07
CCI-all vs. usual care	86	-0.02±0.03	67	0.01±0.04		-0.11±0.05	

NAFLD-Liver fat score

CCI-all education	24	3.43(3.84)	18	3.26(3.62)	62	3.92(4.44)	-0.65±0.62
Usual Care	3	3.10(3.63)	1	2.49(3.00)	17	5.14(4.80)	-2.65±1.23
CCI-all vs. usual care	74	0.33±0.50	57	0.78±0.53		-1.23±1.24	

NAFLD-Fibrosis score

CCI-all education	23	-0.23(1.36)	17	-0.25(1.37)	61	-0.18(1.35)	-0.07±0.20
Usual Care	8	-0.80(1.41)	7	-0.82(1.47)	17	-0.71(1.20)	-0.11±0.39
CCI-all vs. usual care	75	0.56±0.18	58	0.57±0.21		0.53±0.36	

Kidney

Anion gap (mmol L⁻¹)

CCI-all education	25	6.83(1.67)	19	6.76(1.68)	67	7.03(1.62)	-0.27±0.24
Usual Care	7	6.93(1.82)	0	6.82(1.86)	19	7.32(1.67)	-0.50±0.47
CCI-all vs. usual care	86	-0.10±0.21	67	-0.06±0.25		-0.29±0.42	

BUN (mg/dL)

CCI-all education	25	16.88(6.55)	19	17.17(6.05)	67	16.06(7.81)	1.11±0.93
Usual Care	8	16.05(6.25)	1	15.81(6.28)	19	16.89(6.24)	-1.09±1.63
CCI-all vs. usual care	86	0.84±0.81	67	1.37±0.87		-0.84±1.95	

eGFR (mL s⁻¹ m⁻²)

CCI-all education	25	80.48(13.62)	19	80.36(13.53)	67	80.84(13.96)	-0.48±1.94
Usual Care	8	79.17(13.73)	1	79.39(13.72)	19	78.42(14.11)	0.97±3.59
CCI-all vs. usual care	86	1.31±1.70	67	0.97±1.93		2.42±3.64	

Serum creatinine (mg/dL)

CCI-all education	25	0.88(0.24)	19	0.88(0.23)	67	0.90(0.26)	-0.02±0.03
Usual Care	8	0.91(0.25)	1	0.91(0.25)	19	0.90(0.22)	0.004±0.06
CCI-all vs. usual care	86	-0.02±0.03	67	-0.03±0.03		-0.01±0.07	

Uric acid (mg/dL)

CCI-all education	26	5.85(1.46)	19	5.88(1.45)	68	5.77(1.48)	0.11±0.21
Usual Care	1	5.60(1.47)	3	5.58(1.34)	18	5.70(1.92)	0.12±0.39
CCI-all vs. usual care	85	0.25±0.18	67	0.30±0.20		0.07±0.42	

Thyroid

TSH (mIU L⁻¹)

CCI-all education	25	2.32(1.74)	19	2.31(1.81)	67	2.36(1.52)	-0.05±0.25
Usual Care	9	3.80(17.07)	2	4.37(19.17)	18	1.65(1.05)	2.72±4.54
CCI-all vs. usual care	86	-1.48±1.84	68	-2.06±2.33		0.71±0.38	

Free T4 (ng/dL)

CCI-all education	26	0.92(0.17)	19	0.92(0.18)	67	0.91(0.17)	0.01±0.02
Usual Care	0	0.88(0.29)	3	0.87(0.31)	18	0.89(0.16)	-0.02±0.08
CCI-all vs. usual care	86	0.04±0.03	68	0.05±0.03		0.02±0.04	

Other

Beta-hydroxybutyrate (mmol L⁻¹)

CCI-all education	24	0.17(0.15)	18	0.17(0.15)	63	0.19(0.16)	-0.03±0.02
Usual Care	8	0.15(0.13)	5	0.14(0.11)	17	0.20(0.18)	-0.06±0.04
CCI-all vs. usual care	79	0.02±0.20	62	0.03±0.18		-0.01(0.04)	

hsC-reactive protein (nmol L⁻¹)

CCI-all education	24	8.54(14.49)	18	8.92(16.35)	63	7.44(6.41)	1.48±2.12
Usual Care	9	8.89(8.62)	6	9.08(8.91)	18	8.18(7.64)	0.90±2.30
CCI-all vs. usual care	85	-0.34±1.67	67	-0.16±2.10		-0.74±1.79	

White blood cell (k/cumm)

CCI-all education	26	7.24(1.89)	19	7.12(1.82)	67	7.57(2.08)	-0.45±0.27
Usual Care	0	8.14(2.39)	3	8.15(2.30)	19	8.08(2.73)	0.07±0.62
CCI-all vs. usual care	86	-0.90±0.28	67	-1.03±0.31*		-0.51±0.58	

Diabetes Medication

Any diabetes medication,
excluding metformin (%)

CCI-all education	26	56.87±3.07	19	55.67±3.58	68	60.29±5.98	-4.62±7.00
Usual Care	2	66.67±5.08	4	66.18±5.78	19	68.42±10.96	-2.25±12.37
CCI-all vs. usual care	87	-9.80±5.94	68	-10.51±6.80		-8.13±12.71	

Sulfonylurea (%)

CCI-all education	26	23.66±2.63	19	25.77±3.15	68	17.65±4.66	8.13±5.62
Usual Care	2	24.14±4.61	4	22.06±5.07	19	31.58±10.96	-9.52±11.19
CCI-all vs. usual care	87	-0.47±5.28	68	3.71±6.11		-13.93±11.91	

Insulin (%)

CCI-all education	26	29.77±2.83	19	29.38±3.28	68	30.88±5.64	-1.50±6.47
Usual Care	2	45.98±5.37	4	48.53±6.11	19	36.84±11.37	11.69±12.91
CCI-all vs. usual care	87	-16.21±6.07	68	-19.15±6.93		-5.96±12.25	

Thiazolidinedione (%)

CCI-all education	26	1.53±0.76	19	1.55±0.89	68	1.47±01.47	0.08±1.74
Usual Care	2	1.15±1.15	4	1.47±1.47	19	0.00±0.00	1.47±2.79
CCI-all vs. usual care	87	0.38±1.48	68	0.08±1.74		1.47±2.79	

SGLT-2 (%)

CCI-all education	26	10.31±1.88	19	9.79±2.14	68	11.77±3.94	-1.97±4.30
Usual Care	2	14.94±3.84	4	14.71±4.33	19	15.79±8.59	-1.08±9.36
CCI-all vs. usual care	87	-4.64±4.28	68	-4.91±4.83		-4.03±8.71	

DPP-4 (%)

CCI-all education		9.92±1.85		9.28±2.09	68	11.77±3.94	-2.49±4.23
-------------------	--	-----------	--	-----------	----	------------	------------

Usual Care	26	8.05±2.93	19	5.88±2.87	19	15.79±8.59	-9.91±9.06
CCI-all vs. usual care	2	1.88±3.63	4	3.40±3.92		-4.03±8.71	
	87		68				
GLP-1 (%)							
CCI-all education	26	13.36±2.11	19	13.40±2.45	68	13.24±4.14	0.17±4.81
Usual Care	2	16.09±3.96	4	19.12±4.80	19	5.26±5.26	13.85±7.13
CCI-all vs. usual care	87	-2.73±4.31	68	-5.72±5.39		7.97±8.33	
Metformin (%)							
CCI-all education	26	71.37±2.80	19	71.65±3.24	68	70.59±05.57	1.06±6.39
Usual Care	2	60.92±5.26	4	60.29±5.98	19	63.16±11.37	-2.86±12.81
CCI-all vs. usual care	87	10.46±5.96	68	11.36±6.80		7.43±12.12	

Note. Abbreviations: SD, standard deviation; SE, standard error; CCI, continuous care intervention; UC, usual care; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; NAFLD, nonalcoholic fatty liver disease; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rates; TSH, thyroid stimulating hormone; SGLT-2, Sodium glucose co-transporter 2 inhibitor; DPP-4, Dipeptidyl peptidase-4 inhibitor; GLP-1, Glucagon-like peptide 1 receptor agonist.

^aMeeting diabetes reversal criteria at baseline was defined as HbA1c <6.5% and no use of medication for glycemic control other than metformin.

*A significance level of P<0.0012 ensures overall simultaneous significance of P < 0.05 over the 43 variables using Bonferroni correction.

Table 2. Adjusted mean changes over time

	Baseline		1 Year				2 Years			
	Mean ± SE	P	Mean ± SE	P	Change from baseline	P	Meas ± SE	P	Change from baseline	P
Glycemic										
Hemoglobin A1c (%)										
CCI-all education	7.7±0.1		6.3±0.1		-1.3±0.1	6.6 x 10⁻³⁸	6.7±0.1		-0.9±0.1	1.8 x 10⁻¹⁷
Usual Care	7.5±0.2		7.6±0.1		0.2±0.2	0.31	7.9±0.2		0.4±0.2	0.02
CCI-all vs. usual care	0.2±0.2	0.28	-1.3±0.2	2.7 x 10⁻¹⁴			-1.2±0.2	1.3 x 10⁻⁹		
C-Peptide (nmol L ⁻¹)										
CCI-all education	4.33±0.13		3.27±0.14		-1.06±0.13	7.3 x 10⁻¹⁴	3.16±0.12		-1.17±0.13	2.2 x 10⁻¹⁶
Usual Care	4.39±0.24		4.38±0.25		-0.004±0.24	0.99	3.89±0.22		-0.49±0.24	0.04
CCI-all vs. usual care	-0.06±0.28	0.84	-1.12±0.28	9.8 x 10⁻⁵			-0.73±0.26	5.0 x 10 ⁻³		
Fasting glucose (mg/dL)										
CCI-all education	163.67±3.90		127.29±3.62		-36.39±4.47	1.0 x 10⁻¹⁴	134.58±4.13		-	6.8 x 10⁻⁹
Usual Care	151.21±6.93		160.58±6.17		9.38±7.61	0.22	172.89±7.00		29.10±4.88	0.01
CCI-all vs. usual care	12.47±8.02	0.12	-33.30±7.24	6.3 x 10⁻⁶			-38.31±8.21	4.8 x 10⁻⁶	21.68±8.28	
Fasting Insulin (pmol L ⁻¹) ^a										
CCI-all education	27.73±1.26		16.47±1.13		-11.26±1.28	3.2 x 10⁻¹⁶	16.02±1.02		-	2.2 x 10⁻¹⁸
Usual Care	27.57±2.29		26.47±2.06		-1.10±2.30	0.63	24.17±1.84		11.71±1.25	0.13
CCI-all vs. usual care	0.16±2.63	0.95	-10.00±2.38	3.6 x 10⁻⁵			-8.15±2.14	1.7 x 10⁻⁴	-3.40±2.22	

HOMA-IR (insulin derived), all ^a	9.09±0.41		4.85±0.39		-4.24±0.45	3.5 x 10⁻¹⁸	5.27±0.44		-3.82±0.49	3.8 x 10⁻¹³
CCI-all education	9.58±0.73		10.33±0.73		0.75±0.81	0.35	9.95±0.77		0.37±0.83	0.66
Usual Care	-0.49±0.85	0.57	-5.48±0.84	2.9 x 10⁻¹⁰			-4.67±0.89	3.4 x 10⁻⁷		
CCI-all vs. usual care										
HOMA-IR (insulin derived), excluding exogenous users ^a	9.08±0.46		4.56±0.44		-4.53±0.47	6.5 x 10⁻¹⁸	5.25±0.38		-3.83±0.49	2.7 x 10⁻¹³
CCI-all education	8.66±0.92		10.87±0.98		2.21±1.02	0.03	8.26±0.75		-0.40±0.94	0.68
Usual Care	0.43±1.03	0.68	-6.31±1.08	2.2 x 10⁻⁸			-3.01±0.85	5.4 x 10⁻⁴		
CCI-all vs. usual care										
HOMA-IR (C-peptide derived), all ^a	11.25±0.37		8.07±0.38		-3.19±0.39	1.8 x 10⁻¹⁴	7.88±0.35		-3.37±0.39	1.1 x 10⁻¹⁵
CCI-all education	11.04±0.67		11.81±0.71		0.77±0.72	0.28	10.62±0.64		-0.42±0.70	0.55
Usual Care	0.21±0.77	0.78	-3.75±0.81	5.8 x 10⁻⁶			-2.74±0.74	2.5 x 10⁻⁴		
CCI-all vs. usual care										

Metabolic and Body Composition

Weight-clinic (kg)										
CCI-all education	114.56±0.60		100.27±0.86		-14.29±0.71	9.7 x 10⁻⁵⁶	102.62±1.10		-	8.8 x 10⁻²⁸
Usual Care	111.07±1.09		111.71±1.47		0.64±1.17	0.58	112.35±1.90		11.94±0.96	0.43
CCI-all vs. usual care	3.49±1.27	0.01	-11.44±1.71	1.4 x 10⁻¹⁰			-9.73±2.20	1.5 x 10⁻⁵	1.28±1.63	
Spine bone mineral density (kg)	1.21±0.01	—	1.22±0.01	—	0.01±0.01	0.11	1.22±0.01	—	0.01±0.01	0.02
CCI-all education										
Central abdominal fat (kg)										
CCI-all education	5.89±0.07	—	4.62±0.08	—	-1.27±0.07	1.3 x 10⁻⁴²	4.99±0.10	—	-0.90±0.08	1.6 x 10⁻²¹

Android: gynoid ratio										
CCI-all education	1.27±0.02	—	1.18±0.02	—	-0.09±0.1	2.4 x 10⁻¹³	1.20±0.02	—	-0.07±0.01	4.7 x 10⁻⁸
Lower extremities lean mass (kg)										
CCI-all education	18.74±0.16	—	17.41±0.15	—	-1.33±0.10	5.9 x 10⁻³¹	17.38±0.17	—	-1.36±0.12	1.3 x 10⁻²¹
Cardiovascular										
Systolic blood pressure (mmHg)	131.7±0.9		125.3±0.9		-6.5±1.1	3.3 x 10⁻⁸	125.9±1.0		-5.8±1.2	2.4 x 10⁻⁶
CCI-all education	130.3±1.6		129.5±1.6		-0.9±1.9	0.66	129.9±1.8		-0.5±2.1	0.83
Usual Care	1.4±1.8	0.43	-4.2±1.8	0.02			-3.9±2.1	0.06		
CCI-all vs. usual care										
Diastolic blood pressure (mmHg)	81.8±0.5		78.1±0.6		-3.7±0.7	5.4 x 10⁻⁸	78.7±0.6		-3.1±0.7	3.3 x 10⁻⁵
CCI-all education	82.1±1.0		81.3±1.0		-0.8±1.1	0.47	81.6±1.1		-0.6±1.3	0.65
Usual Care	-0.3±1.1	0.76	-3.2±1.1	0.41			-2.8±1.3	0.03		
CCI-all vs. usual care										
Total cholesterol (mg/dL)										
CCI-all education	184.4±2.7		192.8±3.4		8.4±3.1	0.01	194.1±3.5		9.7±3.6	0.01
Usual Care	181.2±4.9		179.4±6.1		-1.8±5.5	0.75	180.9±6.2		-0.3±6.4	0.96
CCI-all vs. usual care	3.3±5.7	0.57	13.5±7.0	0.06			13.3±7.2	0.07		
LDL-cholesterol (mg/dL)										
CCI-all education	103.5±2.2		114.1±2.5		10.6±2.5	2.5 x 10⁻⁵	114.6±2.8		11.1±2.8	1.1x 10⁻⁴
Usual Care	100.0±4.2		88.9±4.9		-11.2±4.7	0.02	90.9±5.1		-9.1±5.1	0.08
CCI-all vs. usual care	3.6±4.8	0.46	25.2±5.6	8.9 x 10⁻⁶			23.7±5.9	7.0x 10⁻⁵		

HDL-cholesterol (mg/dL)										
CCI-all education	41.8±0.9		49.5±0.9		7.8±0.8	4.4 x 10⁻¹⁹	49.5±1.0		7.8±0.9	2.7 x 10⁻¹⁶
Usual Care	38.7±1.4		37.2±1.7		-1.5±1.4	0.30	42.5±1.7		3.8±1.6	0.02
CCI-all vs. usual care	3.1±1.6	0.06	12.4±2.0	1.1 x 10⁻⁹			7.1±2.0	4.1x 10⁻⁴		
Triglycerides (mg/dL) ^b										
CCI-all education	197.2±9.1		148.9±10.1		-48.3±13.7	7.4 x 10⁻¹⁶	153.3±10.4		-43.9±14.0	6.2 x 10⁻⁹
Usual Care	282.9±45.1		314.5±61.4		31.6±74.6	0.35	209.5±18.5		-73.4±55.9	0.75
CCI-all vs. usual care	-85.7±30.1	0.09	-165.5±39.0	1.5 x 10⁻⁸			-56.2±19.0	7.1 x 10⁻⁵		
Liver										
ALT (Units/L) ^a										
CCI-all education	29.16±0.97		21.53±0.88		-7.63±1.02	7.7 x 10⁻¹³	23.00±0.91		-6.16±0.95	4.0 x 10⁻¹⁰
Usual Care	25.84±1.72		26.98±1.51		1.14±1.73	0.51	26.80±1.57		0.96±1.62	0.56
CCI-all vs. usual care	3.31±1.99	0.10	-5.45±1.77	0.002			-3.80±1.84	0.04		
AST (Units/L) ^a										
CCI-all education	22.50±0.64		19.07±0.58		-3.43±0.69	1.1 x 10⁻⁶	19.78±0.57		-2.72±0.66	5.1 x 10⁻⁵
Usual Care	21.51±1.13		23.37±1.00		1.86±1.19	0.12	23.19±0.99		1.68±1.14	0.14
CCI-all vs. usual care	0.99±1.31	0.45	-4.30±1.17	2.8 x 10⁻⁴			-3.41±1.16	3.5 x 10 ⁻³		
ALP (Units/L)										
CCI-all education	74.13±1.42		64.34±1.44		-9.78±0.98	1.9 x 10⁻²⁰	64.50±1.58		-9.63±1.19*	1.8 x 10⁻¹⁴
Usual Care	78.55±2.53		79.05±2.55		0.50±1.65	0.76	82.47±2.76		3.92±2.00	0.05
CCI-all vs. usual care	-4.42±2.94	0.13	-14.71±2.97	1.2 x 10⁻⁶			-17.97±3.22	5.1 x 10⁻⁸		

Bilirubin (mg/dL) ^a										
CCI-all education	0.53±0.01		0.53±0.02		-0.001±0.01	0.92	0.52±0.02		-0.01±0.01	0.45
Usual Care	0.55±0.02		0.57±0.03		0.03±0.02	0.16	0.52±0.03		-0.03±0.02	0.15
CCI-all vs. usual care	-0.01±0.03	0.64	-0.04±0.03	0.18			0.01±0.03	0.80		
NAFLD-Liver fat score ^a										
CCI-all education	3.29±0.21		1.34±0.19		-1.95±0.22	2.0 x 10⁻¹⁶	0.71±0.20		-2.58±0.22	2.9 x 10⁻²⁵
Usual Care	3.20±0.38		3.79±0.35		0.59±0.40	0.14	3.02±0.37		-0.17±0.40	0.66
CCI-all vs. usual care	0.09±0.44	0.83	-2.45±0.40	4.2 x 10⁻⁹			-2.32±0.43	1.6 x 10⁻⁷		
NAFLD-Fibrosis score										
CCI-all education	-0.31±0.06		-0.95±0.07		-0.64±0.06	4.0 x 10⁻²²	-0.78±0.08		-0.47±0.08	2.3 x 10⁻⁹
Usual Care	-0.45±0.11		-0.19±0.12		0.27±0.12	0.01	-0.24±0.14		0.21±0.14	0.12
CCI-all vs. usual care	0.14±0.13	0.27	-0.77±0.14	4.4 x 10⁻⁸			-0.54±0.16	0.001		
Kidney										
Anion gap (mmol L ⁻¹)										
CCI-all education	6.83±0.11		7.12±0.13		0.29±0.15	0.05	7.29±0.13		0.46±0.14	0.003
Usual Care	6.92±0.19		7.74±0.22		0.82±0.25	0.001	7.80±0.22		0.88±0.24	3.2 x 10⁻⁴
CCI-all vs. usual care	-0.09±0.22	0.68	-0.63±0.25	0.01			-0.51±0.25	0.04		
BUN (mmol L ⁻¹) ^a										
CCI-all education	16.40±0.32		18.46±0.37		2.06±0.36	3.8 x 10⁻⁸	17.41±0.40		1.01±0.43	0.02
Usual Care	16.18±0.56		15.83±0.63		-0.35±0.61	0.57	16.21±0.68		0.03±0.72	0.97
CCI-all vs. usual care	0.22±0.65	0.74	2.63±0.74	4.0 x 10⁻⁴			1.20±0.90	0.14		
eGFR (mL s ⁻¹ m ⁻²)										
CCI-all education	80.53±0.78		82.50±0.78		1.97±0.67	0.004	83.26±0.80		2.73±0.72	1.6 x 10⁻⁴
Usual Care	78.70±1.39		79.56±1.36		0.86±1.13	0.45	79.12±1.39		0.42±1.21	0.73
CCI-all vs. usual care	1.82±1.61	0.26	2.94±1.59	0.07			4.14±1.63	0.01		

Serum creatinine (μmol L ⁻¹) ^a										
	0.88±0.01		0.83±0.01		-0.04±0.01	5.3 x 10⁻⁶	0.85±0.01		-0.03±0.01	0.003
CCI-all education	0.90±0.02		0.87±0.02		-0.03±0.02	0.07	0.88±0.02		-0.01±0.02	0.39
Usual Care	-0.02±0.02	0.37	-0.04±0.02	0.12			-0.04±0.02	0.12		
CCI-all vs. usual care										
Uric acid (μmo L ⁻¹)										
CCI-all education	5.83±0.09		5.82±0.10		-0.01±0.08	0.90	5.72±0.10		-0.11±0.09	0.20
Usual Care	5.67±0.16		5.44±0.18		-0.24±0.14	0.09	5.13±0.18		-0.54±0.16	6.2 x 10⁻⁴
CCI-all vs. usual care	0.16±0.19	0.39	0.39±0.21	0.06			0.59±0.21	0.005		
Thyroid										
TSH (mIU L ⁻¹) ^a										
CCI-all education	2.16±0.08		1.89±0.07		-0.28±0.07*	1.3 x 10⁻⁴	1.90±0.08		-0.22±0.09	0.01
Usual Care	1.94±0.14		1.92±0.13		-0.01±0.12	0.92	2.04±0.14		0.11±0.16	0.49
CCI-all vs. usual care	0.23±0.16	0.15	-0.04±0.15	0.79			-0.10±0.16	0.52		
Free T4 (pmol L ⁻¹) ^a										
CCI-all education	0.91±0.01		0.92±0.01		0.01±0.01	0.04	0.93±0.01		0.01±0.01	0.01
Usual Care	0.85±0.02		0.89±0.02		0.04±0.02	0.53	0.90±0.02		0.05±0.02	0.25
CCI-all vs. usual care	0.06±0.02	0.003	0.03±0.03	0.23			0.02±0.03	0.34		
Other										
Beta-hydroxybutyrate (mmol L ⁻¹) ^a										
	0.18±0.01		0.27±0.02		0.09±0.02	6.8 x 10⁻⁷	0.27±0.02		0.09±0.02	4.7 x 10⁻⁵
CCI-all education	0.14±0.02		0.17±0.03		0.03±0.03	0.43	0.18±0.04		0.03±0.04	0.38
Usual Care	0.03±0.02	0.11	0.10±0.04	0.01			0.09±0.04	0.03		
CCI-all vs. usual care										

hsC-reactive protein (nmol L ⁻¹) ^a	7.45±0.42		5.01±0.46		-2.44±0.40	2.4 x 10⁻⁹	4.69±0.40		-2.76±0.37	6.9 x 10⁻¹³
CCI-all education	9.03±0.75		9.06±0.81		0.03±0.69	0.96	8.38±0.74		-0.65±0.65	0.32
Usual Care	-1.58±0.87	0.07	-4.05±0.94	2.1 x 10⁻⁵			-3.69±0.86	2.3 x 10⁻⁵		
CCI-all vs. usual care										
White blood cell (k/cumm)										
CCI-all education	7.22±0.12		6.52±0.13		-0.70±0.10	6.6 x 10⁻¹¹	6.68±0.15		-0.54±0.13	4.3 x 10⁻⁵
Usual Care	8.12±0.22		8.16±0.23		0.04±0.17	0.82	8.07±0.27		-0.05±0.23	0.82
CCI-all vs. usual care	-0.90±0.26	5.3 x 10⁻⁴	-1.64±0.27*	2.3 x 10⁻⁹			-1.39±0.32	1.6 x 10⁻⁵		

Note. Ns for continuous care intervention =262 and Ns for usual care=87. Unless otherwise noted, estimates reported were obtained from linear mixed-effects models which provide adjusted means and mean changes, controlling for baseline age, sex, race, body mass index, and insulin use. This maximum likelihood-based approach uses all available repeated data, resulting in an intent-to-treat analysis. A significance level of $P < 0.0012$ ensures overall simultaneous significance of $P < 0.05$ over the 43 variables using Bonferroni correction. Abbreviations: SE, standard error; CCI, continuous care intervention; UC, usual care; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; NAFLD, nonalcoholic fatty liver disease; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rates; TSH, thyroid stimulating hormone.

^aVariable was positively skewed and after removing the top 1% of values, skew and kurtosis values fell within acceptable ranges. Analyses were conducted on data excluding the top 1% of values for each variable, although due to the maximum likelihood approach all cases were still included in the analyses.

^bVariable was positively skewed and a natural log transformation was performed. The linear mixed-effects model analysis including covariates was conducted on the transformed variable and significance values provided are from the transformed analysis. However, because transformed numbers are difficult to interpret, non-transformed and unadjusted means, mean changes, and standard errors for participants who completed the study visit were computed and provided in the table.


Legends

Figure 1. Flow chart of participants in each stage of the study from recruitment to 2 years post-enrollment and analysis.



Figure 2. Adjusted mean changes from baseline to 2-years in the CCI group for (A) HbA1c, (B) Fasting insulin, (C) Weight, (D) Central Abdominal Fat [CAF], (E) Systolic Blood Pressure, (F) Diastolic Blood Pressure (G) Alanine aminotransferase (ALT), and (H) High sensitive C-reactive protein (hsCRP).

Figure 3. Medication and insulin dose changes from baseline to 2 years for CCI and UC group completers. (A) Percent of completers taking diabetes medications, excluding metformin. (B) Mean \pm SE prescribed insulin dose among baseline users. (C) Frequency of medication dosage and use change among prescribed users by diabetes medication class.



Figure 1



14 **Figure 2**




15




22

(e)




29

(g)




30

(f)



(h)



37


38

39

40

41 **Figure 3**


42 **a**



49



50 **b**

51



61

c



62 **Supplementary Data**

63

64 **Table of contents**

65

66 Supplementary Method.....2

67

68 Supplementary Results.....6

69

70 Supplementary Discussion.....7

71

72 Supplementary Table 1.....9

73

74 Supplementary Table 2.....10

75

76 Supplementary Table 3.....13

77

78 Supplementary Table 4.....21

79

80 Supplementary Table 5.....22

81

82 Supplementary Figure 1.....24

83

84 Supplementary Figure 2.....25

85

86 Supplementary Figure 3.....26

87

88 Supplementary Figure 4.....27

89

90 Supplementary References.....28

91

92 TREND Statement Checklist37

93

Supplementary Method

Study Interventions

Continuous care intervention (CCI)

Briefly, participants in the CCI were provided access to a web-based software application (app), which was used to provide telemedicine communication, online resources and biomarker tracking tools. The participants used the app to upload and monitor their reportable biomarkers including body weight and blood glucose and beta-hydroxybutyrate (BHB). Biomarkers allowed for daily feedback to the care team and individualization of patient instruction. Frequency of reporting was personalized over time based on care needs. Participants were advised to achieve nutritional ketosis (blood BHB level at 0.5 to 3.0 mmol L⁻¹) through sufficient carbohydrate restriction (initially <30g day⁻¹ but gradually increased based on personal carbohydrate tolerance and health goals, primarily control of glucose and weight). Participants' daily protein intake was initially targeted at a level of 1.5g kg⁻¹ of a medium-frame ideal weight body and further individualized based on biomarkers. Participants were instructed to include sufficient dietary fat in meals to achieve satiety without tracking energy intake. Nutrition education directed consumption of monounsaturated and saturated fat with sufficient intake of omega-3 and omega-6 polyunsaturated fats. The participants were also encouraged to consume sufficient fluid, vitamins and minerals including sodium and magnesium, especially if signs of mineral deficiency were encountered (e.g. decreased circulating volume)(1,2).

The web-based app was also used by participants to communicate with their remote care team consisting of a health coach and medical provider. The remote care team provided education and support regarding dietary changes, behavior modification techniques for maintenance of lifestyle changes and actively directed changes for diabetes and antihypertensive medications as part

113 of the intervention. Metformin prescriptions were continued except for contraindication, intolerance, or patient request given its efficacy
114 for T2D prevention [3]. Education modules covered core concepts related to the dietary changes for achieving nutritional ketosis, and
115 adaptation to and maintenance of the diet(1,2). Participants selected their preferred education mode (CCI-virtual, n=126 or CCI-onsite,
116 n=136) during recruitment. The CCI-virtual group received care and education primarily via app-based communication. The CCI-onsite
117 group received care and education via clinic-based group meetings (weekly for 12 weeks, bi-weekly for 12 weeks, monthly for 6 months,
118 and then quarterly in the second year). All participants had access to the app for communication with their care team, online resources,
119 biomarker tracking and the opportunity to participate in an online peer community for social support.

120 ***Usual Care (UC)***

121 The participants recruited for usual care (UC) received care from their primary care physician or endocrinologist and were
122 counseled by a registered dietician as part of a diabetes education program. These participants received the American Diabetes
123 Association (ADA) recommendations on nutrition, lifestyle and diabetes management(3). No modification of their care was made for
124 the study. This group was used as a reference control to study the effect of disease progression over 2 years in a cohort of participants
125 prospectively recruited from the same geography and healthcare system. Figure 1 depicts the study flow from recruitment to 2 years
126 post-enrollment.

127

128 **Body composition measures**

129 The CCI participants' total body composition was measured at baseline, one year and two years using dual-energy X-ray
130 absorptiometry (DXA) (Lunar GE Prodigy, Madison, WI). Participants were scanned while wearing light clothing using standard clinical

131 imaging procedures. The scans obtained were analyzed using GE Encore software(v11.10, Madison, WI). In many obese patients, full
132 body scans were not obtained due to the scanner not accomodating the patient's complete body resulting in issues such as cropping
133 of the arms and/or overlapping of arms with the chest(4,5). To address these limitations, changes in bone density and fat and lean
134 mass were assessed using subregions rather than the full body scan. We assessed changes in the bone mass by evaluating total
135 spine bone mineral density (BMD) from baseline to 2 years(6). For assessment of fat mass, we manually selected the central abdominal
136 fat (CAF) region using the software and evaluated the changes in CAF over time, as previously suggested for overweight
137 individuals(4,7). Furthermore, we assessed changes in the android:gynoid (A/G) ratio by time. Due to lack of proper arm lean mass
138 measurement, we analyzed the lower extremities lean mass (LELM) to assess weight-related changes in lean mass over time(8,9).

139 **Statistical analyses**

140 All analyses were conducted using SPSS statistical software (Version 25.0, Armonk, NY). First, we examined the assumptions
141 of normality and linearity. According to Kline's (2011) (10) guidelines, 14 outcomes (i.e., fasting insulin, insulin and C-peptide-derived
142 HOMA-IR scores, triglycerides, ALT, AST, bilirubin, N-LFS, BUN, serum creatinine, TSH, Free T4, hsCRP, and BHB) were positively
143 skewed. We explored two approaches to handling the skewed variables: natural log-transformations and removing the top 1% of values.
144 For N-LFS which includes both positive and negative values, a modulus log-transformation was performed instead of a natural log-
145 transformation(11). For most variables, both approaches resulted in new skew and kurtosis values within the acceptable range. One
146 variable (triglycerides) was only corrected via log-transformation, whereas two variables (C-peptide-derived HOMA-IR and TSH) were
147 only corrected by removing the top 1% of values. For the other variables, we conducted sensitivity analyses to compare the two
148 approaches. Because the results did not differ between the approaches and because interpretation of outcomes is more difficult with

149 transformed variables, we report results from the approach of removing the top 1% of values for all variables except triglycerides. For
150 triglycerides, analyses were performed and p-values reported on the log-transformed variable but the means and standard errors
151 reported were computed from the untransformed variable. Next, we ran independent sample t-tests to examine differences in baseline
152 characteristics between CCI and UC, and completers and dropouts.

153 We performed linear mixed-effects models (LMMs) to assess (1) within-group changes in the continuous study outcomes from
154 baseline to 2 years and (2) between-group differences (CCI vs. UC) in the study outcomes at 2 years. The LMMs included fixed effects
155 for time, group (CCI vs. UC), and a time by group interaction. Covariates included baseline age, sex, race (African American vs. other),
156 BMI, and insulin use. This maximum likelihood-based approach uses all available repeated data, resulting in an intent-to-treat analysis.
157 An unstructured covariance structure was specified for all models to account for correlations between repeated measures.

158 Within-group changes and between-group differences in dichotomous disease outcome variables; i.e., diabetes reversal,
159 diabetes remission (partial or complete) and complete remission(12), metabolic syndrome(13,14), steatosis(15), fibrosis(16) were
160 assessed, controlling for baseline age, sex, race, time since diagnosis, BMI, and insulin use. For this set of analyses, multiple imputation
161 was used to replace missing values from baseline and 2 years with a set of plausible values, facilitating an intent-to-treat analysis (all
162 ns=262). Missing values were estimated from 40 imputations (17) from logistic regression. Within-group changes from baseline to 2
163 years and between-group differences at 2 years were assessed using generalized estimating equations with binary logistic models and
164 unstructured covariance matrices.

165 We also examined changes in participants' diabetes medication use. First, we compared rates of diabetes medication use within
166 groups from baseline to 2 years using McNemar's test with continuity correction when appropriate. Next, we calculated the proportion

167 of participants in each group with each diabetes medication class eliminated, reduced, not changed, increased, or added. Paired t-
168 tests were used to assess within-group changes in insulin dosages from baseline to 2 years among participants taking insulin at
169 baseline and among participants taking insulin at both baseline and 2 years.

170 We conducted a second set of the analyses with 2-year completers only. Results of the completers-only analyses appear in
171 eTable 3 and 5. Given that 2 different modes (virtual and onsite) were utilized for delivery of the CCI group educational content, we
172 also conducted another set of analyses to assess whether differences existed between the groups on all analyses of primary outcomes.
173 As in our prior time points (1,18), no group differences were found; thus, the data from the two CCI educational groups were combined
174 for this report. For all study analyses, nominal significance levels (P) are presented in the tables. A significance level of $P<0.0012$
175 ensures overall simultaneous significance of $P<0.05$ over the 43 variables using Bonferroni correction.

176

177 **Supplementary Results**

178 ***Safety and adverse events***

179 During the second year of intervention, nine adverse events were reported including: one breast cancer diagnosis, one mycosis
180 fungoides, one onset of atrial fibrillation (Afib) with heart failure, one onset of migraine, two cases of chest pain (one resulting in stent
181 placement), one pulmonary effusion, and two pulmonary embolisms (one following orthopedic surgery and one with benign ovarian
182 mass/Afib). In the UC group, adverse events occurring in the first year were previously reported(1), and in the second year, adverse
183 events occurred in six participants: one death from liver cancer, one hospitalization from recurrent seizure, one ureteropelvic junction

184 obstruction from kidney stone, one cerebrovascular accident with left side weakness and sensory disturbances, one chest pain requiring
185 percutaneous coronary intervention, and one deep vein thrombosis.

186 **Supplementary Discussion**

187 ***Lower extremities lean mass (LELM)***

188 In this study, the CCI group had a reduction (7.0%, 1.3kg) in the calculated LELM. Most lean mass loss was encountered in the first
189 year without further reduction in year 2. Studies have reported that obese adults have about 20% higher thigh muscle mass than those
190 with normal weight(19,20). The reduced upper body load burden achieved through weight loss might explain the reduction of LELM.
191 This reflects an appropriate post-weight decrease in muscle mass rather than muscle deficiency(21,22). Weight loss (~10%) induced
192 by energy restriction resulted in slightly higher lean mass loss than the CCI (8.4% appendicular lean mass and 7.6% total lean mass
193 loss at 20 weeks)(23). Total lean mass loss from 10% weight reduction by bariatric surgery is reported in the range of 7.3 to 15.9% from
194 baseline(24,25). Greater weight loss is usually associated with more lean mass loss(26-28). Approximately 25% of diet-induced weight
195 loss (without exercise) often arises from FFM(29). In the present intervention, FFM loss contributed an estimated 14% to the lower
196 extremity weight loss. The lower proportion of FFM loss in the CCI group, despite higher percentage of weight loss, may be due to the
197 adequate dietary protein recommendations (30,31). Since ~73% of FFM is water, the observed reduction of LELM in the first year of
198 intervention may have arisen from natriuresis and water loss during keto-adaptation(32,33).

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220 **Supplementary Table 1**

221 Equations for calculating HOMA-IR (insulin-derived), HOMA-IR (c-peptide derived), LDL-cholesterol, NAFLD liver fat score (NLF) and
222 NAFLD fibrosis score (NFS)

223

Score	Equation
HOMA-IR (insulin derived)	[fasting insulin (mU/L) x fasting glucose (mg/dL)]/ 405
HOMA-IR (c-peptide derived)	Calculation performed using spreadsheet downloaded from http://www.dtu.ox.ac.uk/homacalculator/
Friedewald LDL-cholesterol	total cholesterol (mg/dL) - HDL cholesterol (mg/dL) - [TG (mg/dL)/5]
NAFLD liver fat score (N-LFS)	-2.89 + 1.18 x metabolic syndrome (yes=1 or no=0) + 0.45 x type 2 diabetes (yes=2 or no=0)* + 0.15 x fasting insulin (mU/l) + 0.04 x fasting serum AST (U/L) – 0.94 x AST/ALT
NAFLD fibrosis score (NFS)	-1.675 + 0.037 × Age (yrs) + 0.094 × BMI (kg/m ²) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio – 0.013 × Platelet (×10 ⁹ /L) –0.66 × Albumin (g/dl)

224

225 **Supplementary Table 2**

226
227 Criteria and cut-offs for diabetes reversal, diabetes partial remission, diabetes complete remission, metabolic syndrome, steatosis and
228 absence of fibrosis

229
230

Disease outcomes	Criteria and cut-offs used for assignment
Diabetes reversal	Sub-diabetic hyperglycemia and normoglycemia (HbA1c below 6.5%), without medications except metformin
Diabetes partial remission(12)	Sub-diabetic hyperglycemia of at least 1 year duration, HbA1c level between 5.7-6.5%, without any medications (two HbA1c measurements)
Diabetes complete remission(12)	Normoglycemia of at least 1 year duration, HbA1c below 5.7%, without any medications (two HbA1c measurements)
Metabolic syndrome(13,14)	Assigned according to the new International Diabetes Federation (IDF) and National Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATP III)] classification. Metabolic syndrome is assigned if any three of the following five factors were listed:

- 1) **Central obesity** defined using BMI and waist circumference: ≥ 40 inches for male and ≥ 37 inches for female. Those missing waist circumference information, if BMI $\geq 30\text{kg/m}^2$, central obesity is assumed.
- 2) **Raised triglycerides**: ≥ 150 mg/dL (1.7 mmol/L)
- 3) **Reduced HDL-cholesterol**: < 40 mg/dL (1.03mmol/L) in males or < 50 mg/dL (1.29mmol/L) in females
- 4) **Raised fasting blood glucose**: ≥ 100 mg/dL
- 5) **Raised blood pressure**: systolic BP ≥ 130 or diastolic BP $\geq 85\text{mmHg}$

For those with missing data:

- A) If patient is missing more than two criteria from the five factors, he/she is classified as missing or no assignment.
- B) If patient is missing two or fewer criteria excluding central obesity and any of the remaining criteria were classified positive (present); he/she is assigned as “having metabolic syndrome”
- C) If patient is missing only one criteria excluding central obesity and if the remaining criteria were classified negative (not present), he/she is assigned as “not having metabolic syndrome”.

Suspected steatosis(15)	Optimal cut-off point of > -0.640 predicts increased liver fat content (suspected steatosis) with sensitivity of 86% and specificity of 71%.
Absence of fibrosis(16)	Optimal cut-off point of < -1.455 predicts absence of significant fibrosis with a negative predictive value of 93%.

231
232
233

234 **Supplementary Table 3**

235 Descriptives and results of completer-only analyses

236

	Baseline			1 Year			2 Years			
	N	Mean (SD) or \pm SE	Range	N	Mean (SD) or \pm SE	Range	N	Mean (SD) or \pm SE	Range	P
Glycemic										
Hemoglobin A1c (%) ^a										
CCI-all education	262	7.6(1.5)	5.3-13.6	204	6.2(0.9)	4.50-12.0	183	6.6(1.3)	4.8-12.5	9.9×10^{-16}
Usual Care	87	7.6(1.8)	5.1-12.5	76	7.9(1.8)	5.3-13.6	68	8.2(2.0)	5.6-13.8	0.01
CCI-all vs. usual care										1.9×10^{-10}
C-Peptide (nmol L ⁻¹) ^a										
CCI-all education	248	4.4(2.2)	0.01-12.4	196	3.4(1.8)	0.01-12.4	173	3.3(1.7)	0.01-11.4	1.5×10^{-15}
Usual Care	79	4.2(2.5)	0.3-11.2	63	4.3(2.8)	0.3-15.3	57	3.4(1.9)	0.3-7.4	0.76
CCI-all vs. usual care										0.25
Fasting glucose (mg/dL) ^a										
CCI-all education	258	160.8(61.4)	70.0-418.0	205	124.0(35.2)	71.0-	179	131.1(44.8)	42.0-363.0	5.9×10^{-8}
Usual Care	86	156.2(72.6)	40.0-356.0	76	166.9(83.0)	318.0	67	181.2(90.1)	65.0-466.0	0.10
CCI-all vs. usual care						50.0-514.0				3.6×10^{-6}
Fasting Insulin (pmol L ⁻¹) ^{a,c}										
CCI-all education	248	28.6(23.9)	2.5-209.5	196	18.0(24.2)	0.9-285.7	172	17.5(25.2)	0.6-312.4	1.9×10^{-15}
Usual Care	79	29.1(24.9)	0.4-122.6	63	30.8(33.7)	2.3-205.1	57	23.0(18.7)	4.3-114.5	0.98
CCI-all vs. usual care										0.004
HOMA-IR (insulin derived), all ^{a,c}										
CCI-all education	220	9.0(6.2)	1.0-42.4	181	4.8(3.7)	0.7-20.4	162	5.9(9.9)	0.1-118.0	2.1×10^{-12}
Usual Care	78	10.6(9.1)	0.05-44.7	61	12.7(12.6)	0.4-52.6	56	10.4(9.3)	1.2-39.3	0.28
CCI-all vs. usual care										2.2×10^{-5}

HOMA-IR (insulin derived), excluding exogenous users ^{a,c}	157	8.8(5.6)	1.0-35.2	156	4.6(3.5)	0.7-18.8	143	6.0(10.3)	0.2-118.0	0.003
CCI-all education	42	9.4(8.3)	1.3-41.5	28	13.2(14.2)	1.5-51.7	22	8.4(7.6)	1.2-34.0	0.24
Usual Care										0.01
CCI-all vs. usual care										
HOMA-IR (C-peptide derived), all ^{a,c}										
CCI-all education	244	11.7(7.4)	0.04-66.7	190	8.1(4.4)	0.05-32.3	164	8.0(4.2)	0.03-27.8	5.4 x 10 ⁻¹⁴
Usual Care	78	11.1(7.6)	0.6-45.5	60	12.5(10.7)	0.6-66.7	55	12.6(19.5)	0.5-142.9	0.60
CCI-all vs. usual care										0.02
Metabolic and Body Composition										
Weight-clinic (kgs) ^a										
CCI-all education	257	116.5(25.9)	63.4-215.6	187	101.1(22.2)	55.4-	147	102.5(21.9)	58.5-181.0	4.6 x 10 ⁻²⁶
Usual Care	83	105.6(22.1)	71.0-170.6	73	109.3(24.5)	166.7	53	110.5(25.2)	71.2-166.5	0.35
CCI-all vs. usual care						74.6- 172.8				2.7 x 10 ⁻⁵
Spine bone mineral density (kg) ^a										
CCI-all education	238	1.2(0.2)	0.8-1.8	195	1.2(0.2)	0.9-1.7	167	1.2(0.2)	0.8-1.8	0.01
Central abdominal fat (kg) ^a										
CCI-all education	237	5.8(1.7)	1.9-10.8	195	4.6(1.7)	1.3-9.7	167	4.9(1.7)	1.5-10.1	1.9 x 10 ⁻²²
Android: gynoid ratio ^a										
CCI-all education	238	1.3(0.3)	0.7-2.5	195	1.2(0.3)	0.7-2.3	167	1.2(0.3)	0.7-2.4	1.6 x 10 ⁻⁶
Lean leg mass (kg) ^a										
CCI-all education	238	18.5(4.1)	10.3-30.1	195	17.6(4.4)	10.6-33.7	167	17.3(4.2)	10.4-34.6	1.2 x 10 ⁻²³
Cardiovascular										
Systolic blood pressure (mmHg) ^a										
CCI-all education	260	131.9(14.1)	92.0-180.0	188	125.7(11.9)		150	126.1(13.1)	92.0-160.0	1.8 x 10 ⁻⁵

Usual Care	79	129.8(13.6)	102.0-170.0	73	129.1(15.3)	92.0-160.0	53	129.9(11.1)	102.0-152.0	0.92
CCI-all vs. usual care						102.0-170.0				0.03
Diastolic blood pressure (mmHg) ^a										
CCI-all education	260	82.1(8.3)	60.0-110.0	188	78.0(7.5)	56.0-100.0	150	78.7(8.0)	60.0-100.0	1.5 x 10 ⁻⁴
Usual Care	79	82.0(8.9)	62.0-110.0	72	81.3(9.5)	100.0	53	81.7(7.2)	62.0-96.0	0.95
CCI-all vs. usual care						48.0-100.0				0.01
Total cholesterol (mg/dL) ^a										
CCI-all education	247	183.6(41.2)	97.0-349.0	196	190.2(45.1)	105.0-320.0	171	193.4(43.6)	106.0-320.0	0.004
Usual Care	79	183.8(45.8)	91.0-339.0	63	180.2(61.1)	320.0	56	181.8(57.0)	320.0	0.82
CCI-all vs. usual care						94.0-404.0			102.0-430.0	0.13
LDL-cholesterol (mg/dL) ^a										
CCI-all education	232	102.5(32.9)	29.0-211.0	188	112.3(38.3)	30.0-240.0	162	114.7(38.4)	36.0-231.0	9.4 x 10 ⁻⁵
Usual Care	70	101.5(36.2)	29.0-204.0	53	89.3(29.5)	240.0	50	93.9(32.3)	36.0-165.0	0.12
CCI-all vs. usual care						29.0-159.0				7.4 x 10 ⁻⁴
HDL-cholesterol (mg/dL) ^a										
CCI-all education	247	42.2(13.4)	12.0-117.0	196	50.1(15.9)	15.0-111.0	170	51.1(15.8)	23.0-96.0	2.8 x 10 ⁻¹⁵
Usual Care	79	37.6(11.2)	15.0-66.0	63	35.9(12.3)	111.0	56	42.3(10.3)	21.0-65.0	0.11
CCI-all vs. usual care						13.0-77.0				0.02
Triglycerides (mg/dL) ^{a,d}										
CCI-all education	247	197.2(143.4)	46.0-1432.0	196	148.9(141.8)	41.0-1308.0	170	153.3(135.5)	42.0-1356.0	9.2 x 10 ⁻⁹
Usual Care	79	282.9(401.2)	84.0-2781.0	63	314.5(487.7)	78.0-3639.0	56	209.5(138.7)	74.0-708.0	0.80
CCI-all vs. usual care										0.01
Liver										
ALT (Units/L) ^{1,a,c}										
CCI-all education	257	30.7(22.8)	7.0-258.0	205	21.8(11.7)	7.0-111.0	179	22.5(11.5)	7.0-99.0	2.0 x 10 ⁻⁹
Usual Care	86	27.7(19.8)	8.0-153.0	75	28.3(20.3)	7.0-103.0	66	28.9(19.1)	7.0-112.0	0.44

CCI-all vs. usual care										0.05
<hr/>										
AST (Units/L) ^{a,c}										
CCI-all education	257	23.7(15.2)	7.0-130.0	205	19.1(6.9)	8.0-73.0	178	19.5(6.3)	10.0-59.0	2.0 x 10 ⁻⁴
Usual Care	86	23.9(19.4)	9.0-156.0	74	24.6(16.2)	10.0-120.0	66	24.9(14.8)	12.0-79.0	0.15
CCI-all vs. usual care										0.005
<hr/>										
ALP (Units/L) ^a										
CCI-all education	256	74.1(22.1)	25.0-172.0	205	64.8(21.2)	27.0-	178	64.0(19.6)	28.0-160.0	1.2 x 10 ⁻¹⁴
Usual Care	86	77.4(26.3)	25.0-154.0	74	78.7(26.7)	174.0	66	81.5(31.1)	32.0-179.0	0.08
CCI-all vs. usual care						35.0-169.0				3.5 x 10 ⁻⁷
<hr/>										
Bilirubin (mg/dL) ^{a,c}										
CCI-all education	256	0.5(0.2)	0.2-1.6	205	0.5(0.2)	0.2-2.1	178	0.5(0.3)	0.2-2.3	0.39
Usual Care	86	0.6(0.3)	0.2-1.5	74	0.6(0.3)	0.2-1.7	66	0.6(0.4)	0.2-2.5	0.14
CCI-all vs. usual care										0.72
<hr/>										
NAFLD-Liver fat score ^{a,c}										
CCI-all education	243	3.4(3.8)	-2.6-30.9	184	1.5(3.9)	-1.9-42.8	142	0.9(4.3)	-3.4-45.3	1.1 x 10 ⁻²⁰
Usual Care	74	3.1(3.6)	-2.0-16.0	59	4.6(5.4)	-1.0-30.7	44	2.7(3.3)	-1.2-16.4	0.10
CCI-all vs. usual care										1.5 x 10 ⁻⁴
<hr/>										
NAFLD-Fibrosis score ^a										
CCI-all education	238	-0.2(1.4)	-4.0-5.1	173	-0.8(1.1)	-3.3-2.7	132	-0.7(1.2)	-3.8-4.7	1.1 x 10 ⁻¹⁰
Usual Care	75	-0.8(1.4)	-4.6-2.1	60	-0.4(1.5)	-4.6-2.3	40	-0.2(1.4)	-4.7-2.4	0.13
CCI-all vs. usual care										1.7 x 10 ⁻⁴
<hr/>										
Kidney										
<hr/>										
Anion gap (mmol L ⁻¹) ^a										
CCI-all education	257	6.8(1.7)	2.0-12.0	205	7.1(1.8)	2.0-12.0	179	7.2(1.6)	3.0-12.0	4.9 x 10 ⁻⁴
Usual Care	86	6.9(1.8)	3.0-12.0	76	7.8(1.9)	4.0-13.0	66	7.7(1.9)	4.0-13.0	1.8 x 10 ⁻⁴
CCI-all vs. usual care										0.08
<hr/>										

BUN (mg/dL)^{a,c}										
CCI-all education	258	16.9(6.6)	7.0-70.0	205	19.0(7.8)	8.0-86.0	179	17.8(6.6)	7.0-57.0	0.05
Usual Care	86	16.1(6.2)	5.0-36.0	76	16.0(5.8)	6.0-44.0	67	16.4(6.8)	6.0-49.0	0.86
CCI-all vs. usual care										0.15
eGFR (mL s⁻¹ m⁻²)^a										
CCI-all education	258	80.5(13.6)	26.0-90.0	205	82.7(12.0)	31.0-90.0	178	83.0(11.4)	40.0-90.0	9.9 x 10 ⁻⁴
Usual Care	86	79.2(13.7)	33.0-90.0	76	80.1(13.0)	29.0-90.0	66	79.1(14.9)	21.0-90.0	0.84
CCI-all vs. usual care										0.02
Serum creatinine (mg/dL)^{a,c}										
CCI-all education	258	0.9(0.2)	0.5-2.2	205	0.8(0.2)	0.4-1.9	179	0.8(0.2)	0.5-1.8	0.004
Usual Care	86	0.9(0.2)	0.5-2.2	76	0.9(0.2)	0.5-1.9	66	0.9(0.4)	0.6-3.2	0.76
CCI-all vs. usual care										0.15
Uric acid (mg/dL)^a										
CCI-all education	261	5.9(1.5)	2.7-10.2	203	5.9(1.5)	1.7-10.5	179	5.8(1.5)	2.9-10.1	0.19
Usual Care	85	5.6(1.5)	2.9-10.5	72	5.4(1.4)	2.9-9.0	55	5.0(1.2)	2.6-8.0	0.003
CCI-all vs. usual care										0.002
Thyroid										
TSH (mIU L⁻¹)^{a,c}										
CCI-all education	259	2.3(1.7)	0.03-15.3	203	1.9(1.1)	0.02-8.1	179	2.0(1.2)	0.2-10.9	0.08
Usual Care	86	3.8(17.1)	0.03-159.9	74	4.8(23.9)	0.1-207.8	60	2.9(6.2)	0.03-49.3	0.79
CCI-all vs. usual care										0.31
Free T4 (ng/dL)^{a,c}										
CCI-all education	260	0.9(0.2)	0.6-1.9	203	0.9(0.2)	0.6-1.8	179	0.9(0.2)	0.6-1.8	0.34
Usual Care	86	0.9(0.3)	0.4-3.0	73	0.9(0.2)	0.2-1.8	57	0.9(0.3)	0.6-2.8	0.03
CCI-all vs. usual care										0.47
Other										

Beta-hydroxybutyrate (mmol L ⁻¹) ^{a,c}										
CCI-all education	248	0.2(0.2)	0.04-1.1	196	0.3(0.3)	0.04-2.3	170	0.3(0.4)	0.05-2.7	1.1 x 10 ⁻⁵
Usual Care	79	0.2(0.1)	0.05-0.7	63	0.2(0.2)	0.04-1.5	55	0.2(0.3)	0.04-1.4	0.17
CCI-all vs. usual care										0.09
hsC-reactive protein (nmol L ⁻¹) ^{a,c}										
CCI-all education	249	8.5(14.5)	0.5-207.5	203	5.6(6.9)	0.2-42.4	179	6.1(9.7)	0.2-87.4	1.6 x 10 ⁻¹²
Usual Care	85	8.9(8.6)	0.4-35.6	71	10.4(14.6)	0.3-103.5	55	8.3(8.5)	0.4-30.7	0.30
CCI-all vs. usual care										0.001
White blood cell (k/cumm) ^a										
CCI-all education	260	7.2(1.9)	3.5-13.3	205	6.5(1.8)	2.7-13.0	180	6.6(2.0)	2.4-14.5	9.0 x 10 ⁻⁵
Usual Care	86	8.1(2.4)	3.6-14.7	75	8.2(2.4)	2.9-13.8	60	8.0(2.6)	4.1-19.3	0.85
CCI-all vs. usual care										8.0 x 10 ⁻⁵
Diabetes Medication										
Any diabetes medication, excluding metformin (%) ^b										
CCI-all education	262	56.9±3.1	—	218	28.0±3.1	—	194	26.8±3.2	—	1.3 x 10 ⁻¹¹
Usual Care	87	66.7±5.1		78	75.6±4.9		58	79.3±5.4		0.004
Sulfonylurea (%) ^b										
CCI-all education	262	23.7±2.6	—	218	00.0±0.0	—	194	00.0±0.0	—	4.2 x 10 ⁻¹²
Usual Care	87	24.1±4.6		78	25.6±5.0		58	29.3±6.0		0.23
Insulin (%) ^b										
CCI-all education	262	29.8±2.8	—	218	14.7±2.4	—	194	11.3±2.3	—	9.1 x 10 ⁻⁹
Usual Care	87	46.0±5.4		78	51.3±5.7		58	55.2±6.6		0.23
Thiazolidinedione (%) ^b										
CCI-all education	262	1.5±0.8	—	218	0.5±0.5	—	194	2.6±1.1	—	0.73

Usual Care	87	1.2±1.2		78	1.3±1.3		58	6.9±3.4		0.25
SGLT-2 (%) ^b										
CCI-all education	262	10.3±1.9	—	218	0.9±0.7	—	194	3.1±1.3	—	0.01
Usual Care	87	14.9±3.8		78	16.7±4.3		58	13.8±4.6		0.69
DPP-4 (%) ^b										
CCI-all education	262	9.9±1.9	—	218	6.4±1.7	—	194	6.7±1.8	—	0.42
Usual Care	87	8.1±2.9		78	11.5±3.6		58	8.6±3.7		0.99
GLP-1 (%) ^b										
CCI-all education	262	13.4±2.1	—	218	15.1±2.4	—	194	10.8±2.2	—	0.42
Usual Care	87	16.1±4.0		78	20.5±4.6		58	27.6±5.9		0.18
Metformin (%) ^b										
CCI-all education	262	71.4±2.8	—	218	64.2±3.3	—	194	63.9±3.5	—	0.05
Usual Care	87	60.9±5.3		78	60.3±5.6		58	63.8±6.4		0.18

237 *Note.* All means and standard deviations or standard errors are without any adjustments and include all available data for the time
 238 point. Abbreviations: SD, standard deviation; CCI, continuous care intervention; UC, usual care; HOMA-IR, homeostatic model
 239 assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST,
 240 aspartate aminotransferase; ALP, alkaline phosphatase; NAFLD, nonalcoholic fatty liver disease; BUN, blood urea nitrogen; eGFR,
 241 estimated glomerular filtration rates; TSH, thyroid stimulating hormone; SGLT-2, Sodium glucose co-transporter 2 inhibitor; DPP-4,
 242 Dipeptidyl peptidase-4 inhibitor; GLP-1, Glucagon-like peptide 1 receptor agonist.
 243 ^aP-values representing changes from baseline to 2 years and between group-differences at 2 years were obtained from linear mixed-
 244 effects models. Covariates in the model included baseline age, sex, race, body mass index, and insulin use. Only participants with
 245 both baseline and 2 year data for the outcome were included in the analysis.
 246 ^bP-values representing changes in the proportions of participants taking medication from baseline to 2 years were obtained from
 247 McNemar's tests, with continuity correction when appropriate. Only participants with both baseline and 2 year data for the medication
 248 were included in the analysis.
 249 ^cVariable was positively skewed and after removing the top 1% of values, skew and kurtosis values fell within acceptable ranges.
 250 Analyses were conducted on data excluding the top 1% of values for each variable.

251 ^dVariable was positively skewed and a natural log transformation was performed. The linear mixed-effects model analysis including
252 covariates was conducted on the transformed variable.
253
254
255

256 **Supplementary Table 4.**

257

258 Disease outcomes in CCI and UC participants after 2 years (Intent-to-treat analysis with imputation)

Disease Outcomes	Continuous Care Intervention (n=262)			Usual Care (n=87)			Between group
	Baseline	2 Years	P	Baseline	2 Years	P	P
Diabetes Reversal (%)	12.1±2.0	53.5±3.4	<0.0x10 ⁻³⁶	16.4±4.5	9.3±3.9	0.04	<0.0x10 ⁻³⁶
Diabetes Remission (%)^a	—	17.6±2.5	—	—	2.4±1.7	—	5.1x10 ⁻⁹
Complete Remission (%)	—	6.7±1.6	—	—	0.0±0.0	—	1.1x10 ⁻⁵
Metabolic Syndrome (%)	89.1±2.0	61.9±4.0	4.9x10 ⁻¹⁵	92.4±3.3	85.9±5.1	0.24	4.7x10 ⁻⁷
Suspected Steatosis (%)	95.8±1.4	67.4±4.2	<0.0x10 ⁻³⁶	94.7±3.0	89.0±5.1	0.16	2.5x10 ⁻⁷
Absence of Fibrosis (%)	18.3±2.5	30.8±4.0	1.4x10 ⁻⁵	24.9±5.4	15.9±5.8	0.08	4x10 ⁻³

259 *Note.* Percentages and standard errors are provided. Estimates were obtained from generalized estimating equation models which
 260 provide adjusted proportions, controlling for baseline age, sex, race, time since diagnosis, body mass index, and insulin use. Multiple
 261 imputation was used to replace missing values, facilitating intent-to-treat analyses. A significance level of P<0.0012 ensures overall
 262 simultaneous significance of P < 0.05 over the 43 study variables using Bonferroni correction.

263 ^aDiabetes remission includes both partial and complete remission.

264 **Supplementary Table 5.**
265 Disease outcomes in CCI and UC participants after 2 years (Completers-only analysis)

Disease Outcomes	Continuous Care Intervention					Usual Care (n=87)					Between group	
	N	Baseline	N	2 Years	P	N	Baseline	N	2 Years	P	P	
Diabetes Reversal (%)	262	12.2±2.0	181	54.7±3.7	<0.0x10 ⁻³⁶	87	20.7±4.4	57	10.5±4.1	0.07	5.4x10 ⁻¹⁵	
Diabetes Remission (%)^a	—	—	208	18.8±2.7	—	—	—	79	2.5±1.8	—	1.6x10 ⁻⁸	
Complete Remission (%)	—	—	210	6.7±1.7	—	—	—	81	0.0±0.0	—	1.1x10 ⁻⁴	
Metabolic Syndrome (%)	262	88.6±2.0	154	63.0±3.9	9.9x10 ⁻¹¹	81	91.4±3.1	54	87.0±4.6	0.51	8.9x10 ⁻⁵	
Suspected Steatosis (%)	243	96.3±1.2	142	67.6±3.9	7.7x10 ⁻¹³	74	94.6±2.6	44	88.6±4.8	0.40	3.9x10 ⁻⁵	
Absence of Fibrosis (%)	238	18.1±2.5	132	29.6±4.0	0.003	75	28.0±5.2	40	17.5±6.1	0.58	0.09	

266 *Note.* All percentages and standard errors are without any adjustments and include all available data for the time point. P-values
267 representing within-group changes from baseline to 2 years and between-group differences at 2 years were obtained from generalized
268 estimating equation models. Covariates in the model included baseline age, sex, race, time since diagnosis, body mass index, and
269 insulin use. Only participants with both baseline and 2 year data for the outcome were included in the analysis. A significance level of
270 $P < 0.0012$ ensures overall simultaneous significance of $P < 0.05$ over the 43 study variables using Bonferroni correction.

271 ^aDiabetes remission includes both partial and complete remission.

272

273

Supplementary Figures Legend

Supplementary Figure 1. Adjusted mean changes (CCI versus UC) from baseline to 2-years in (A) HbA1c, (B) Fasting insulin, (C) Weight.

Supplementary Figure 2. Stratification of participants based on weight change (%) categories in each intervention groups, UC and CCI, among completers. Category <5% includes participants with weight gain.


Supplementary Figure 3. Adjusted mean changes (CCI versus UC) from baseline to 2-years in (A) Systolic Blood Pressure, (B) Diastolic Blood Pressure, (C) Alanine aminotransferase (ALT), and (D) High sensitive C-reactive protein (hsCRP).

Supplementary Figure 4. Cumulative relative frequency (%) of percentage participants reporting BHB $\geq 0.5\text{mM}$ at first, second and both years of the study. The differences in the distribution of participants reporting BHB $\geq 0.5\text{mM}$ between one and two years are illustrated in the figure.

294 **Supplementary Figure 1**


295 **a**

296




297

298 **b**




299

c




306
307
308
309

Supplementary Figure 2




310 **Supplementary Figure 3**


311 **a**




320 **b**



c




d



327

328 **Supplementary Figure 4**

329



343

344

Supplementary References (S)

1. Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. *Diabetes Ther* 2018; 9: 583-612.
2. Bhanpuri NH, Hallberg SJ, Williams PT, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. *Cardiovasc Diabetol* 2018; 17: 56 <https://doi.org/10.1186/s12933-018-0698-8>.
3. Standards of Medical Care in Diabetes - 2018: Summary of Revisions. *Diabetes Care* 2018; 41: S1-S1
4. Brownbill RA, and Ilich JZ. Measuring body composition in overweight individuals by dual energy x-ray absorptiometry. *BMC Med Imaging* 2005; 5: 1 doi:10.1186/1471-2342/5/1.
5. Rothney MP, Brychta RJ, Schaefer EV, et al. Body composition measured by dual-energy X-ray absorptiometry half-body scans in obese adults. *Obesity* 2009; 17: 1281-1286.
6. Chun KJ. Bone densitometry. *Semin Nucl Med* 2011; 41: 220-228.
7. Kamel EG, McNeill G, Van Wijk CWV. Usefulness of anthropometry and DXA in predicting intra-abdominal fat in obese men and women. *Obes Res* 2000; 8: 36-42.
8. Reid KF, Naumova EN, Carabello RJ, et al. Lower extremity muscle mass predicts functional performance in mobility-limited elders. *J Nutr Health Aging* 2008; 12: 493-498.
9. Moon JJ, Park SG, Ryu SM, et al. New skeletal muscle mass index in diagnosis of sarcopenia. *J Bone Metab* 2018; 25: 15-21.
10. Kline RB. Principles and practice of structural equation modeling (3rd ed.) 2011 New York: The Guilford Press.

- 363 11. John JA, Draper NR. An alternative family of transformations. *Appl Statist* 1980; 29: 190-197.
- 364 12. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? ADA Consensus Statement. *Diabetes Care* 2009; 32:
365 2133-2135.
- 366 13. International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. *IDF*
367 *Communications* 2006; 1-24.
- 368 14. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech* 2009; 2: 231-237.
- 369 15. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and
370 genetic factors. *Gastroenterology* 2009; 137: 865-872.
- 371 16. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients
372 with NAFLD. *Hepatology* 2007;45: 846-854.
- 373 17. Graham JW, Olchowski AE, et al. How many imputations are really needed? Some practical clarifications of multiple imputation
374 theory. *Prevention Sci* 2007; 8: 206-213.
- 375 18. McKenzie A, Hallberg S, Creighton BC, et al. A novel intervention including nutritional recommendations reduces hemoglobin
376 A1c level, medication use, and weight in type 2 diabetes. *JMIR Diabetes* 2017; 2: e5.
- 377 19. Lafortuna CL, Tresoldi D, Rizzo G. Influence of body adiposity on structural characteristics of skeletal muscle in men and
378 women. *Clin Physiol Funct Imaging* 2014; 34: 47-55
- 379 20. Choi SJ, Files DC, Zhang T, et al. Intramyocellular lipid and impaired myofiber contraction in normal weight and obese older
380 adults. *J Gerontol A Biol Sci Med Sci* 2016; 71: 557-564.

21. Mingrone G, Marino S, DeGaetano A, et al. Different limit to the body's ability of increasing fat-free mass. *Metabolism* 2001;50: 1004-1007.
22. Forbes GB, Welle SL. Lean body mass in obesity. *Int J Obes* 1983; 7: 99-107.
23. Bopp MJ, Houston DK, Lenchik L, et al. Lean mass loss is associated with low protein intake during dietary-induced weight loss in postmenopausal women. *J Am Diet Assoc* 2008; 108: 1216-1220.
24. Ciangura C, Bouillot JL, Lloret-Linares C, et al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. *Obesity* 2010; 18: 760-765.
25. Varma S, Brown T, Clark J, et al. Comparative effects of medical vs. surgical weight loss on body composition in a randomized trial. *Diabetes* 2018; 67 (S1): <https://doi.org/10.2337/db18-2460-PUB>.
26. Zalesin KC, Franklin BA, Lillystone MA, et al. Differential loss of fat and lean mass in the morbidly obese after bariatric surgery. *Met Syndrome and Related Dis* 2010; 8: 15-20.
27. Redmon JB, Reck KP, Raatz SK, et al. Two year outcome of a combination of weight loss therapies for type 2 diabetes. *Diabetes Care* 2005; 28: 1311-1315.
28. Maghrabi AH, Wolski K, Abood B, et al. Two year outcomes on bone density and fracture incidence in patients with T2DM randomized to bariatric surgery vs. intensive medical therapy. *Obesity* 2015; 23: 2344-2348.
29. Heymsfield SB, Gonzalez MCC, Shen W, et al. Weight loss composition is one-fourth fat-free mass: A critical review and critique of this widely cited rule. *Obes Rev* 2014; 15: 310-321.

30. Davis PG, Phinney SD. Differential effects of two very low calorie diets on aerobic and anaerobic performance. *Int J Obesity* 1990; 14: 779-787.
31. Kim JE, O'Connor LE, Sands LP, et al. Effects of dietary protein intake on body composition changes after weight loss in older adults: a systematic review and meta-analysis. *Nutr Review* 2016; 74: 210-224
32. Frigolet ME, Ramos Barragan VE, Tamez Gonzalez M. Low-carbohydrate diets: a matter of love or hate. *Ann Nutr Metab* 2011; 28: 320-334.
33. Kolanowski J, Bodson A, Desmecht P, et al. On the relationship between ketonuria and natriuresis during fasting and upon refeeding in obese patients. *Eur J Clin Invest*. 1978; 8: 277-282.
34. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systemic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014; 384: 766-781.
35. Knop FK, Taylor R. Mechanism of metabolic advantages after bariatric surgery. *Diabetes Care* 2013; 36: 5287-
36. Steven S, Lim EL, Taylor R. Dietary reversal of type 2 diabetes motivated by research knowledge. *Diabet Med* 2010; 27: 724-725.
37. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. *Obes Surg* 2013; 23: 93-102.
38. Hamdan K, Somers S, Chand M. Management of late postoperative complications of bariatric surgery. *Br J Surgery* 2011; 98: 1345-1355.

39. Wing RR, Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type II diabetes: does including intermittent very-low calorie diet improve outcome? *Am J Med* 1994; 97: 354-362.
40. Goday A, Bellido D, Sajoux I, et al. Short-term safety, tolerability and efficacy of a very low- calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus. *Nutr Diabetes* 2016;6: e230
41. Westman EC, Yancy WS, Mavropoulos JC, Marquart M, McDuffie JR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. *Nutr Metab* 2009; 19: 36, doi:10.1186/1743-7075-5-36.
42. Kirk JK, Graves DE, Craven TE, et al. Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis. *J Am Diet Assoc* 2008; 108: 91-100.
43. Volek JS, Sharman MJ, Gomez AL, et al. Comparison of a very low-carbohydrate and low-fat diet on fasting lipids, LDL subclasses, insulin resistance, and postprandial lipemic responses in overweight women. *J Am Coll Nutr* 2004; 23: 177-184.
44. Seshadri P, Iqbal N, Stern L, et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. *Am J Med* 2004; 117: 398-405.
45. McKenzie A, Hallberg S, Creighton BC, et al. A novel intervention including nutritional recommendations reduces hemoglobin A1c level, medication use, and weight in type 2 diabetes. *JMIR Diabetes* 2017; 2: e5.
46. White WB, Cannon CP, Heller CR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med* 2013; 369: 1327-1335.

47. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *Lancet Diabetes Endocrinol* 2018; 6: 105-113.
48. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015; 373: 2117-2118.
49. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, mediterranean, or low-fat diet. *N Engl J Med* 2008; 359: 229-241.
50. Iqbal N, Vetter ML, Moore RH, et al. Effects of a low-intensity intervention that prescribed a low-carbohydrate vs. a low fat diet in obese, diabetic participants. *Obesity* 2010; 18: 1733-1738
51. Haimoto H, Iwata M, Wakai K, Umegaki H. Long-term effects of a diet loosely restricting carbohydrates on HbA1c levels, BMI and tapering of sulfonylureas in type 2 diabetes: A 2-year follow-up study. *Diab Res Clin Prac* 2008; 79: 350-356.
52. Steinberg DM, Tate DF, Bennett GG, Ennett S, Samuel-Hodge C, Ward DS. The efficacy of a daily self-weighing weight loss intervention using smart scales and email. *Obesity* 2013; 21: 1789-1797.
53. Arterburn D, Bogart A, Coleman KJ, et al. Comparative effectiveness of bariatric surgery versus nonsurgical treatment of type 2 diabetes among severely obese adults. *Obes Res Clin Pract* 2013; 7: e258-e268.
54. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty person/ten-country panel. *J Intern Med* 2006; 259: 247-258.
55. Verges B. Lipid modification in type 2 diabetes: the role of LDL and HDL. *Fundam Clin Pharmacol* 2009; 23: 681-685.

- 449 56. Menke A, Knowler WC, and Cowie CC. Physical and metabolic characteristics of persons with diabetes and prediabetes.
450 Chapter 9 in Diabetes in America, 3rd ed. Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg
451 EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M,
452 Fradkin JE, eds, Bethesda, MD, National Institutes of Health, NIH Pub No. 17-1468[p.1-55].
- 453 57. Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk
454 prediction among individuals with and without diabetes. Diabetes Care 2005; 28: 1916-1921.
- 455 58. Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb 2018; 25: 771-785.
- 456 59. Gross BA, Goss AM. A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin
457 sensitivity in adults at risk of type 2 diabetes. J Nutr 2015; 145: 177S-183S.
- 458 60. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis,
459 gout and uric calculous disease. Am J Clin Nutr 1956; 4: 20-31.
- 460 61. Jakobsen MU, Berentzen T, Sorensen TIA, et al. Abdominal obesity and fatty liver. Epidemiol Rev 2007; 29:77-87.
- 461 62. Bouchi R, Nakano Y, Fukuda T, et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis,
462 albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocr J 2017;
463 64: 269-281.
- 464 63. Shimabukuro M, Higa M, Yamakawa K, et al. Miglitol, α -glycosidase inhibitor, reduces visceral fat accumulation and
465 cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study. Int J Cardiol 2013; 167:
466 2108-2113.

- 467 64. Gabriely I, Ma XH, Yang XM, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an
468 adipokine-mediated process? *Diabetes* 2002; 51: 2951-2958.
- 469 65. Garcia-Ruiz I, Solis-Munoz P, Fernandez-Moreira D, et al. Omentectomy prevents metabolic syndrome by reducing appetite
470 and body weight in a diet induced obesity rat model. *Sci Rep* 2018; 8: 1540.doi: 10.1038/s41598-018-19973.
- 471 66. Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action. *Diabetes Care*
472 2017; 40: 419-430.
- 473 67. Verrijen A, Francque S, Van Gaal L. The role of visceral adipose tissue in the pathogenesis of non-alcoholic fatty liver disease.
474 *European Endocrinology* 2011; 7: 96-103.
- 475 68. Wu X, Huang Z, Wang X. et al. Ketogenic diet compromises both cancellous and cortical bone mass in mice. *Calcif Tissue Int*
476 2017; 101: 412-421.
- 477 69. Zengin A, Kropp B, Chevalier Y, et al. Low-carbohydrate, high-fat diets have sex-specific effects on bone health in rats. *Eur J*
478 *Nutr* 2016; 55: 2307-2320.
- 479 70. Willi SM, Oexmann MJ, Wright NM, Collop NA, Key LL Jr. The effects of a high-protein, low-fat, ketogenic diet on adolescents
480 with morbid obesity: body composition, blood chemistries and sleep abnormalities. *Pediatric* 1998; 101: 61-67
- 481 71. Colica C, Merra G, Gasbarrini A, et al. Efficacy and safety of very low-calorie ketogenic diet: a double blind randomized
482 crossover study. *Eur Rev Med Pharmacol Sci* 2017; 21: 2274-2289.
- 483 72. Moreno B, Bellido D, Sajoux I, et al. Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the
484 treatment of obesity. *Endocrine* 2014; DOI 10.1007/s12020-014-0192-3

73. Bertoli S, Trentani C, Ferraris C, De Giorgis V, Veggiotti P, Taglibue A. Long-term effects of a ketogenic diet on body composition and bone mineralization in GLUT-1 deficiency syndrome: A case series. *Nutrition* 2014; 30: 726-728.

491

492

493 TREND Statement Checklist

Paper Section/Topic	Item No.	Descriptor	Reported?	
			✓	Pg #
TITLE and ABSTRACT				
Title and Abstract	1	• Information on how units were allocated to interventions		3
		• Structured abstract recommended		3
		• Information on target population or study sample		3
INTRODUCTION				
Background	2	• Scientific background and explanation of rationale		4-5
		• Theories used in designing behavioral interventions		N/A
METHODS				
Participants	3	• Eligibility criteria for participants, including criteria at different levels in recruitment/sampling plan (e.g., cities, clinics, subjects)		6, suppl material
		• Method of recruitment (e.g., referral, self-selection), including the sampling method if a systematic sampling plan was implemented		6, suppl material
		• Recruitment setting		6, suppl material
		• Settings and locations where the data were collected		6, suppl material
Interventions	4	• Details of the interventions intended for each study condition and how and when they were actually administered, specifically including:		6, suppl material, ref 7
		○ Content: what was given?		6, suppl material, ref 7
		○ Delivery method: how was the content given?		6, suppl material, ref 7
		○ Unit of delivery: how were subjects grouped during delivery?		6, suppl material, ref 7
		○ Deliverer: who delivered the intervention?		6, suppl

			material, ref 7
		o Setting: where was the intervention delivered?	6, suppl material, ref 7
		o Exposure quantity and duration: how many sessions or episodes or events were intended to be delivered? How long were they intended to last?	6, suppl material, ref 7
		o Time span: how long was it intended to take to deliver the intervention to each unit?	6, suppl material, ref 7
		o Activities to increase compliance or adherence (e.g., incentives)	6, suppl material, ref 7
Objectives	5	• Specific objectives and hypotheses	5-8
Outcomes	6	• Clearly defined primary and secondary outcome measures	6-8
		• Methods used to collect data and any methods used to enhance the quality of measurements	6-8
		• Information on validated instruments such as psychometric and biometric properties	N/A
Sample size	7	• How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules	N/A
Assignment method	8	• Unit of assignment (the unit being assigned to study condition, e.g., individual, group, community)	6-8
		• Method used to assign units to study conditions, including details of any restriction (e.g., blocking, stratification, minimization)	6-8
		• Inclusion of aspects employed to help minimize potential bias induced due to non-randomization (e.g., matching)	6-8, suppl material
Blinding (masking)	9	• Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed	N/A
Unit of Analysis	10	• Description of the smallest unit that is being analysed to assess intervention effects (e.g., individual, group, or community)	6-8
		• If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis)	8, suppl material
Statistical methods	11	• Statistical methods used to compare study groups for primary methods outcome(s), including complex methods for correlated data	8, suppl material

		<ul style="list-style-type: none"> • Statistical methods used for additional analyses, such as subgroup analyses and adjusted analysis 	8, suppl material
		<ul style="list-style-type: none"> • Methods for imputing missing data, if used 	8, suppl material
		<ul style="list-style-type: none"> • Statistical software or programs used 	8, suppl material
RESULTS			
Participant flow	12	<ul style="list-style-type: none"> • Flow of participants through each stage of the study: enrollment, assignment, allocation and intervention exposure, follow-up, analysis (a diagram is strongly recommended) 	9, Figure 1
		<ul style="list-style-type: none"> ○ Enrollment: the numbers of participants screened for eligibility, found to be eligible or not eligible, declined to be enrolled, and enrolled in the study 	9, Figure 1
		<ul style="list-style-type: none"> ○ Assignment: the numbers of participants assigned to a study condition 	9, Figure 1
		<ul style="list-style-type: none"> ○ Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention 	9, Figure 1
		<ul style="list-style-type: none"> ○ Follow-up: the number of participants who completed the follow-up or did not complete the follow-up (i.e., lost to follow-up), by study condition 	9, Figure 1
		<ul style="list-style-type: none"> ○ Analysis: the number of participants included in or excluded from the main analysis, by study condition 	9, Figure 1
		<ul style="list-style-type: none"> • Description of protocol deviations from study as planned, along with reasons 	9, Figure 1
Recruitment	13	<ul style="list-style-type: none"> • Dates defining the periods of recruitment and follow-up 	6
Baseline data	14	<ul style="list-style-type: none"> • Baseline demographic and clinical characteristics of participants in each study condition 	8, Table 1
		<ul style="list-style-type: none"> • Baseline characteristics for each study condition relevant to specific disease prevention research 	N/A
		<ul style="list-style-type: none"> • Baseline comparisons of those lost to follow-up and those retained, overall and by study condition 	8, Table 1
		<ul style="list-style-type: none"> • Comparison between study population at baseline and target population of interest 	N/A
Baseline equivalence	15	<ul style="list-style-type: none"> • Data on study group equivalence at baseline and statistical methods used to control for baseline differences 	Table 1, suppl material
Numbers analyzed	16	<ul style="list-style-type: none"> • Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible 	Table 2, 9-12
		<ul style="list-style-type: none"> • Indication of whether the analysis strategy was "intention to treat" or, if not, description of how non-compliers were treated in the analyses 	Table 2, 9-12

Outcomes and estimation	17	• For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision	Table 2, 9-12
		• Inclusion of null and negative findings	Table 2, 9-12
		• Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any	N/A
Ancillary analyses	18	• Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory	11-12, Suppl material
Adverse events	19	• Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals)	12, Suppl material
DISCUSSION			
Interpretation	20	• Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study	14-17
		• Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations	14-17
		• Discussion of the success of and barriers to implementing the intervention, fidelity of implementation	14-17
		• Discussion of research, programmatic, or policy implications	14-17
Generalizability	21	• Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in the study, and other contextual issues	14-17
Overall evidence	22	• General interpretation of the results in the context of current evidence and current theory	14-17

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. *American Journal of Public Health*, 94, 361-366. For more information, visit: <http://www.cdc.gov/trendstatement/>